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Introduction to systemic sclerosis
Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterised by endothelial 
dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with resultant 
excessive collagen production and fibrosis. The classification of SSc is based on the extent 
of skin involvement into diffuse cutaneous sclerosis (dcSSc) and limited cutaneous sclerosis 
(lcSSc) (1). Mortality in SSc is high; in a systematic review and a meta-analysis of the literature 
(2) including 2,691 SSc patients in 9 cohort studies, the pooled Standardized Mortality 
Ratio was (SMR) was 3.53. Among 732 deaths, heart involvement was the most frequent 
cause of death (29%), followed by lung involvement (2). In the EULAR Scleroderma Trials 
and Research group (EUSTAR) database (3), 55% of deaths were due to SSc, whereas 45% 
of deaths were thought to be unrelated to SSc. Of the SSc-related deaths, 26% were cardiac 
(predominantly heart failure and arrhythmias), whereas 29% of non-SSc related deaths 
were due to cardiac causes.
Pulmonary involvement in systemic sclerosis 
While virtually any organ system may be involved in the disease process, fibrotic and vascular 
pulmonary manifestations of SSc, including interstitial lung disease (ILD) and pulmonary 
hypertension (PH), are the leading cause of death (4). 
In SSc, the two most common types of direct pulmonary involvement are ILD and PH, which 
together account for 60% of SSc-related deaths (5). While certain pulmonary manifestations 
may occur more commonly in a subset of SSc (i.e. ILD is more common in dcSSc while PH is 
more common in lcSSc) (6), all of the known pulmonary manifestations reported have been 
described in each of the subsets of disease. In the following text, these two complications 
are further discussed.
Interstitial lung disease
Interstitial lung disease is very common in SSc. In early autopsy studies, up to 100% of 
patients were found to have parenchymal involvement (7;8). As many as 90% of patients will 
have interstitial abnormalities on high-resolution computed tomography (HRCT) (9;10) and 
40–75% will have changes in pulmonary function tests (PFTs) (11-13). Parenchymal lung 
involvement often appears early after the diagnosis of SSc, with 25% of patients developing 
clinically significant lung disease within 3–5 years (11). Symptoms and complaints include 
dyspnea (at rest and at exertion), chest tightness and non-productive cough. Risk factors for 




its development include African–American ethnicity, skin score, hypothyroidism and cardiac 
involvement (14;15). Genetic factors, specific serological findings (anti-topoisomerase and 
anti-endothelial cell antibodies predict the presence of lung involvement) and the pattern of 
skin disease (patients with dcSSc have a higher incidence of interstitial disease) all contribute 
(16;17). Predictors of severe restrictive lung disease (defined by a forced vital capacity (FVC) 
less than 50% predicted) include African–American ethnicity (18), male sex, the degree of 
physiological abnormalities at diagnosis (FVC and diffusing capacity of the lung for carbon 
monoxide (DLCO)) and younger age (18;19).
Role of pulmonary function tests in ILD
Screening pulmonary physiology shows a reduction in FVC in 40–75% of patients, with 15% 
having a severe reduction (12;18;20). DLCO is reduced in almost all patients with other PFT 
abnormalities (21;22) and correlates with the extent of lung disease on HRCT(22). DLCO is 
lower in patients with UIP on biopsy (21) and, although FVC and DLCO are both identified 
as adverse prognostic markers (18;19), a declining DLCO is the single most significant 
marker of poor outcome (21). 
Pulmonary hypertension
PH can occur in all forms of SSc and is associated with early mortality. First symptoms and 
complaints include dyspnea at exertion, palpitations and chest discomfort. Patients with SSc 
have the highest prevalence of PH among patients with a collagen vascular disease (CVD) 
(23). The updated clinical classification of PH divides patients into five groups based on 
the aetiology of their PH (24). SSc patients may fall into group 1 (isolated PAH, defined as 
a resting mean pulmonary artery pressure (mPAP) ≥25 mmHg with a pulmonary capillary 
wedge pressure ≤15 mmHg (25), group 2 (PH resulting from left ventricular involvement 
or diastolic dysfunction) and group 3 (PH resulting from ILD/hypoxaemia). Furthermore, 
patients can have combinations of these forms of PH. The prevalence of PH in SSc (SSc-
PH) is variable and depends on the method of detection and the population studied. Using 
transthoracic Doppler echocardiography to screen SSc patients, the prevalence of PAH has 
been reported to range from 13% to 35% (26). However, when right heart catheterisation 
(RHC) is performed on ‘‘high-risk’’ SSc patients (defined as a combination of abnormal 
echocardiography findings, reduced DLCO in the absence of pulmonary fibrosis, a fall in 
DLCO and/or unexplained dyspnoea), a prevalence of 7–13% is found (27). PH can develop 
anytime during the course of SSc (28) and is more common in lcSSc when compared to 
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diffuse disease (29). In the European League against Rheumatism (EULAR) Scleroderma 
Trials and Research database, a multinational open scleroderma cohort with over 3,000 
patients, isolated PH was seen in 9.2% of lcSSc and 5.8% of dcSSc patients. Multiple risk 
factors have been identified including increased age at diagnosis (30), more severe Raynaud’s 
phenomena (31), the presence of digital tip ulcers (32), a diagnosis of lcSSc, decreased 
nailfold capillary density (33) and increased numbers of teleangiectasias on examination 
(33). Specific autoantibodies, including the presence of anti-U3 ribonucleoprotein antibodies 
(34), anti-topoisomerase IIa antibodies and anti-centromere antibodies (35), appear to be 
associated with a higher risk of PH. The presence of anti-Scl70 antibodies is associated with 
progressive ILD and appears to be less associated with PH (31). Patients with SSc-PH are 
older, more severely ill and more likely to be female when compared to idiopathic PH (36).
Role of echocardiography in PH
Transthoracic echocardiography is the most widely used tool to screen for PH in SSc. The 
performance characteristics of echocardiography depend on the population evaluated and 
the cut-off used. Studies show that 55–86% of patients with an echocardiography suggestive 
of PH (right ventricular systolic pressure (RVSP) 30–40 mmHg or higher with or without
symptoms) will have PH on RHC (37). Higher cut-off points for RVSP as well as other 
characteristics of increased pulmonary pressures, such as increased right atrial or 
right ventricular size, decreased right ventricular function, increases the specificity of 
echocardiography for the diagnosis of PH. False positive and false negative results regularly 
occur in patients with mild disease. False negative results have been reported in patients 
earlier in the course of disease (38). 
Role of pulmonary function tests in PH
Reductions in DLCO are very common in SSc. In 19% of all SSc patients isolated reductions 
in DLCO were found (39), but only a minority developed PH. However, a moderate reduction 
(DLCO <55% predicted) in association with an FVC/ DLCO ratio >1.4% (40) or a DLCO 
that is low or declining in the absence of parenchymal lung disease predicts the development 
of PH in SSc (31). Hachulla et al. (41) found that a DLCO <60% predicted in the absence of 
parenchymal lung disease was significantly associated with PH (OR 9.23, 95% CI 2.73–31.15). 
Steen and Medsger (31) found a significantly lower DLCO in patients with PH at an average 
of 4.5 years before the diagnosis of PH (52% versus 81%, p<0.001). In addition, they found 
that a declining DLCO over 15 years strongly predicts the development of PH. 




Importance of management of SSc patients at risk for PH and ILD 
The prevalence of PH in SSc exceeds 10% (8–13%), its presence increases morbidity and 
mortality. Since effective treatments are available (42), screening for PH is appropriate. 
However, despite echocardiography is currently widely used as a first screening tool, it 
lacks sufficient sensitivity and specificity in mildly increased pulmonary arterial pressures 
(43). Therefore, it cannot be used to screen for developing PH, which is now recognized of 
increasing importance in SSc (44). 
As SSc patients who develop significant and progressive interstitial lung disease lung function 
tests and HRCT chest imaging should be considered. In patients with measurable disease, 
the extent of the abnormalities identified is important as patients with mild physiological 
or imaging abnormalities are likely to remain clinically stable. In contrast, those with more 
severe disease are at increased risk for disease progression (45). 
Changes in FVC or DLCO should indicate HRCT chest imaging; evidence of disease 
progression should start a discussion regarding the treatment. Treatment of significant 
interstitial lung disease may include Cyclophosphamide (46), autologous stem cell 
transplantation (47) and/or Mycophenolate Mofetil (for maintenance therapy) in patients 
requiring treatment. A simple stratification scheme developed by Goh et al. (45) utilises 
HRCT extent of disease and lung function tests and provides discriminatory prognostic 
information. Surgical lung biopsy in these patients is not routinely necessary as the clinical 
course and outcome is similar between the major histopathological subsets in SSc-ILD (i.e. 
NSIP and UIP) (21). However, despite its feasibility, the Goh’ score remains qualitative and 
is subjective to limited reproducibility. 
This thesis focuses on the early recognition of complicating pulmonary hypertension 
and interstitial lung disease. In addition it studies the relation between structure and 
function using different imaging and lung function techniques. By doing so, an improved 
characterisation of the individual SSc patient may be achieved facilitating personalized care. 
Cardiopulmonary exercise testing in the evaluation of pulmonary arte-
rial hypertension in systemic sclerosis
Dyspnea on exertion, fatigue and reduced exercise tolerance are common symptoms in 
patients with systemic sclerosis. PH may develop in the course of the disease resulting 
from developing pulmonary vasculopathy (PV). PV impairs dilatation of pulmonary blood 
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vessels in rest and during exercise, giving rise to impaired blood flow. The impedance of the 
respiratory system is thereby affected and results from primarily the reduced compliance of 
the pulmonary vasculature (48). Pulmonary arterial hypertension related to SSc (PAH-SSc) 
is associated with high morbidity and mortality as well as poorer response to therapy and 
worse outcomes compared with the idiopathic form of PAH (iPAH) (49). After three years 
of follow-up, less than 50% of PAH-SSc patients were still alive versus 83% of iPAH patients. 
There is a need to identify variables that predict disease progression early in the course 
of PAH-SSc. These variables must be associated with clinical outcomes and responsive 
to therapeutic intervention (50). Among these new variables, exercise pulmonary 
hemodynamics may promise major determinants of heart failure in PAH-SSc. Exercise stress 
in PAH-SSc as well as in patients with developing PV tests the ability of the diseased heart 
to increase its output and the pulmonary vasculature to respond to an increased blood flow. 
Failure of these adaptations will result in impaired stroke volume increase or even decrease 
(51). During exercise, the increase in mean pulmonary artery pressure (mPAP) in relation 
to oxygen uptake (V’O2) may show either a “takeoff ” or “plateau” pattern. 
Patients with severe exercise induced PAH (EIPAH) and resting PAH will show a “pla teau” 
physiology. In these patients mPAP will increase as well as the pulmonary vascular resistance 
(PVR) dur ing exercise until the cardiac output is compromised and starts to fall. Eventu ally, 
with a decline in cardiac output as a result of right ventricular dysfunction, mPAP will not 
further increase or even fall resulting in a compensatory tachy cardia. In contrast, patients 
with mild to moderate EIPAH showed a “take-off ” physiology, suggesting pulmonary va-
soconstriction during incremental ex ercise. In these patients, mPAP further increases in 
which the cardiac output does not decrease. Therefore, it seems plausible that patients with 
PAH of varying duration and severity will exhibit different mPAP responses to ex ercise (51).
Several studies have been performed to assess the occurrence and or presence of EIPAH in 
SSc (43;44;48;52). Combination of echocardiography and cardiopulmonary exercise testing 
(CPET) in these patients revealed an elevated systolic pulmonary artery pressure (SPAP) 
during right-sided heart catheterization and a low peak oxygen uptake. By discriminating 
patients during CPET using peak oxygen uptake (peak V’O2), low oxygen pulse (V’O2/HR), 
a low oxygen uptake to work rate ratio (ΔV’O2/ΔWR) and an elevated ventilatory equivalent 
for CO2 (V’E/V’CO2) pulmonary vasculopathy could be distinguish from left ventricular 
disease and a normal response (48). Interestingly, several patients showed a marked decrease 
in their oxygen uptake to heart rate increase ratio (ΔV’O2/ΔHR) resulting in a breakpoint 




(48). Furthermore, peak oxygen uptake was significantly lower than in patients not showing 
this response. This breakpoint represents a change in cardiovascular response to exercise by 
an abrupt increase in heart rate since cardiac output cannot effectively in crease by stroke 
volume alone. This indicates that the rise in HR is disproportionally faster than V’O2 as 
work rate increases and may be related to increasing pulmonary arterial pressures. However, 
whether this breakpoint analysis relates to impaired aerobic capacity or impaired stroke 
volumes i.e. pulmonary arterial pressures is not known. 
The aim of chapter 2 is to analyse the V’O2/HR slope breakpoint method in the detection 
of pulmonary vasculopathy by using an automated breakpoint detection algorithm. 
Furthermore, the relation between this novel analysis of V’O2/HR slopes, pulmonary arterial 
pressures and peak oxygen uptake in SSc is discussed. 
Novel assessment of myocardial involvement in systemic sclerosis
Myocardial involvement in SSc may include pericarditis, microvascular coronary artery 
disease, conduction abnormalities and in particular, impaired myocardial contractility 
or relaxation of right or left ventricle with or without heart failure (53). Myocardial 
dysfunction is presumably caused by myocardial fibrosis and inflammation giving rise to 
microangiopathy, vasospasms and poor vasodilator reserve (54). In a post-mortem study, 
myocardial fibrosis was detected in up to 70% of patients with SSc (54). Early diagnosis 
of myocardial involvement therefore plays an important role in the management of these 
patients. 
Conventional echocardiographic assessment of left (LV) and right ventricular (RV) function 
is based on the LV ejection fraction (LVEF) and tricuspid annular plain systolic excursion 
(TAPSE) (55). However, these measurements have shown limited sensitivity for assessment 
of myocardial abnormalities in patients with SSc (53). Tissue Doppler imaging (TDI) assesses 
myocardial tissue velocities and is able to provide information on longitudinal function at 
the mitral valve annular level (56). Results of initial studies using tissue Doppler imaging 
suggested that myocardial velocity and deformation (strain) might be more sensitive than 
conventional measures in identifying subtle cardiac dysfunction in asymptomatic patients 
with SSc (57-59). Furthermore, myocardial analysis by TDI is significantly limited by 
angle dependency and does not allow for the evaluation of all LV segments and of different 
directions of myocardial deformation.
Chapter_1_Maarten.indd   15 26-10-2015   11:35:19
Chapter 1
16
Recently, 2-dimensional speckle-tracking strain analysis has been proposed as a sensitive, 
non-invasive and accurate method for the evaluation of subclinical myocardial dysfunction 
(60). It provides measures of LV regional and global strain in three orthogonal directions 
(longitudinal, circumferential and radial). 
The aim of chapter 3 is to assess LV dysfunction and its relation with functional capacity 
using this novel technique in patients with SSc and controls. Chapter 4 focuses on RV free 
wall strain and its association with pulmonary fibrosis and elevated pulmonary arterial 
pressures in patients with SSc and controls. 
Dyspnea assessment and control of breathing in systemic sclerosis
Humans can sense a wide range of respiratory sensations such as respiratory motion, 
lung position, irritation, urge to cough, chest tightness and sense of effort. Among these 
respiratory sensations, specific aspects such as chest tightness and sense of effort are the most 
important contributors to the sensation of dyspnea (61). In systemic sclerosis, complicating 
interstitial lung disease and pulmonary hypertension may result into dyspnea (46). In SSc, 
an increased impedance of the respiratory system is recognized as the most frequent cause 
of dyspnea (62). The impedance of the respiratory system is influenced by the lung and chest 
wall compliance and the respiratory flow resistance (62). In progressive SSc, reduced chest 
wall and lung compliance may result from limited chest wall excursions and a thickened 
thoracic skin (63;64). Lung volumes and gas transfer studies are related to disease severity 
in systemic sclerosis (46). However, whether the magnitude of dyspnea relates to these 
function tests is not known. 
To assess the respiratory drive as a function of the impedance of the respiratory system, 
resting ventilation (V’E) can be evaluated. However, ventilation, is an imperfect output 
parameter since it is affected by alterations in the impedance of the respiratory system (62). 
Mouth occlusion pressures (MOP) provide an excellent reproducibility and reported normal 
values are independent of age and sex (62). In a study of normal subjects and patients with 
ILD, MOP were able to distinguish between these groups (65). Furthermore, in combination 
with CO2 rebreathing, the respiratory drive to hypercapnia provides insight into the central 
chemoreflex (66). These determinants of the respiratory drive may assess the dyspnea 
sensation more precisely than lung volumes and gas transfer studies do. 




Dyspnea in SSc may also arise from an altered control of breathing (67). Specifically, an 
inappropriate response upon the chemoreflex drive at rest and during exercise to carbon 
dioxide (CO2) may influence their control of breathing (68). The peripheral chemoreflex plays 
in important role in the control of breathing and therefore in the sensation of dyspnea (69). 
It not only ensures oxygen homeostasis, but also helps maintain CO2 levels at rest and during 
exercise (68). The carotid bodies, the site of the peripheral chemoreflex to oxygen, CO2 and 
pH, contain a complex microvascular anatomy in a macrovascular environment. Systemic 
sclerosis related inflammatory and fibrotic responses may cause a diminished peripheral 
chemoreflex response (70). This response may result into an increased susceptibility to 
exercise intolerance and consequently reported dyspnea during exercise (71).
The aim of chapter 5 was to evaluate the respiratory drive at rest and during CO2 rebreathing 
by mouth occlusion pressures (MOP) and their correlation with reported dyspnea. 
Furthermore, the aim of chapter 6 was to assess the peripheral chemoreflex drive at rest 
and during exercise in healthy subjects and SSc patients. 
Quantitative analysis of interstitial lung disease in systemic sclerosis
Clinical risk assessment of organ manifestations in systemic sclerosis (SSc) has revealed 
that interstitial lung disease (ILD) is present in 53% of cases with diffuse cutaneous SSc 
(dcSSC) and in 35% of cases with limited cutaneous SSc (lcSSc) (72). The most common 
pathological finding in lung biopsies of ILD in patients with SSc is nonspecific interstitial 
pneumonia (NSIP), although usual interstitial pneumonitis (UIP) is also occasionally found 
(73). However, discrimination between NSIP or UIP pathology does not improve outcome 
(21). Hence, the discrimination between these subtypes of ILD is limited to computed 
tomography (CT) scanning. 
Currently, chest high-resolution computed tomography (HRCT) is the most reliable means of 
detecting SSc-ILD (74;75). The chest radiograph, although a valuable initial screening tool, is
notoriously insensitive in the detection of SSc-ILD (76). The HRCT profile in SSc-ILD is 
typical of that seen in idiopathic NSIP and most commonly consists of a variable mixture 
of ground-glass attenuation and reticulation, without honeycomb change. However, in a 
minority of patients, honeycomb change is more prominent and is likely to be indicative 
of a histological pattern of UIP (74). Although the relative proportions of ground-glass 
attenuation, reticulation, and honeycombing have been quantified in several clinical studies, 
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this exercise does not, in general, provide clinically useful information. The exception to this 
rule is the occasional patient with prominent ground-glass attenuation which, in the absence 
of traction bronchiectasis, identifies a high likelihood of reversible inflammatory disease. 
Both the severity and the extent of ILD are usually estimated by semi-quantitative scoring 
of a limited number of cross-sectional slices through the lungs (77;78). Clear survival 
discrimination was demonstrated by an easy to perform staging algorithm in combination 
with pulmonary function test data (45). However, despite this benefit visual scoring has 
limited reproducibility because of its subjective nature. In contrast, formal quantification of 
the extent of disease on HRCT is currently widely used in clinical studies but is insufficient 
for routine clinical evaluation due to its complexity and its performance with a lack of 
volume correction (74;79;80).
HRCT data provide a means to quantitatively analyze the structure of the whole lung, since 
inflammation, ground glass opacities, and fibrosis can be quantified by lung densitometry. 
Therefore, objective quantitative techniques by CT densitometry may provide a more 
sensitive measurement, similar to what has been proven in assessing progression of 
pulmonary emphysema by the percentile density method (81). Since these quantitative 
techniques are automated, it is feasible to quantify the entire lungs instead of only a limited 
number of slices, with a smaller chance of missing pathological changes.
Previously, Camiciotolli et al. (79) reported that lung density histogram parameters are more 
reproducible than visual assessment of HRCT and are more closely related to functional, 
exercise, and quality-of-life impairment in SSc. In their evaluation of each patient, they 
calculated the average global density of the lung and included kurtosis and skewness of the 
density histogram of the whole lung. However, this analysis did not provide a single overall 
score for the structure of the lungs, and lung density values were not corrected for lung 
volume. In a recent report, the same investigators clearly demonstrated the need for volume 
correction of density parameters (80). Volume-corrected lung density parameters calculated 
by specific software may be useful outcome measures in evaluating the progression of ILD 
and the response to treatment. 
The aim of chapter 7 focuses is to identify the optimal percentile density threshold by using 
novel quantitative CT densitometry. In addition, we compared the change in percentile 
density score over time with changes in FVC and DLCO.
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Objective: During cardiopulmonary exercise testing (CPET) compromised pulmonary 
vasculature in patients with systemic sclerosis (SSc) may lead to increases in pulmonary 
arterial pressures (PAP) and decreased oxygen uptake. We hypothesized that this may lead 
into a disproportional heart rate (HR) increase with a corresponding V’O2/HR breakpoint 
and relates to systolic PAP at rest. 
Methods: In a prospective design we evaluated V’O2/HR slopes for breakpoints. To 
understand its physiological meaning, we evaluated V’O2/HR and V’O2/mPAP slopes 
for breakpoints in a historic data set of SSc patients, in which CPET and right heart 
catheterization was performed simultaneously. V’O2/HR slopes with a peak oxygen uptake 
outside the normal range were defined as pathologic. 
Results: A breakpoint occurred in both V’O2/mPAP and V’O2/HR slope in 16/34 patients 
in the historic dataset and occurred in the V’O2/mPAP slope at a lower V’O2 in 15 patients. 
In the prospective dataset, 73/121 patients showed a V’O2/HR breakpoint and achieved a 
significantly lower peak oxygen uptake compared to 48/121 patients without a V’O2/HR 
breakpoint (p=0.036). Mean systolic PAP in 41/121 patients with a pathologic V’O2/HR 
slope differed significantly from patients without a pathologic V’O2/HR slope (p=0.027). In 
27/121 patients with a systolic PAP <35 mmHg a pathologic V’O2/HR slope was observed. 
Conclusion: SSc patients with a V’O2/HR breakpoint are characterized by a decreased 
oxygen uptake, likely caused by sudden PAP increases during exercise. Importantly, in 
patients with normal resting SPAP pathologic V’O2/HR slopes were observed. This suggests 
that these patients are at risk for developing pulmonary hypertension. 
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2Introduction
Patients with SSc are at risk for developing pulmonary hypertension (PH) with an estimated 
prevalence of 8–12% (1-3;3;4). In SSc, Doppler echocardiography (DE) is used for screening 
of PH and a SPAP threshold of 35 mmHg is used to define elevated pulmonary pressures 
which may suggest the presence of PH (3;4). CPET is another important tool in the evalua-
tion of patients with suspected PH which reveals impaired gas exchange and might therefore 
be useful as an early detection tool (2;5;6). The oxygen pulse, which normalizes oxygen 
consumption for heart rate, is widely used as an indirect measurement for cardiac stroke 
volume (SV) (7) and is correlated with invasively measured SV (8). Usually reported against 
load or time during exercise (6), it may also be described as the oxygen uptake against heart 
rate (V’O2/HR) (9). Peak oxygen uptake serves as a marker for cardiac performance during 
exercise in patients with PH (10-12). In SSc, elevated systolic pulmonary arterial pressures, 
SPAP ≥35 mmHg, are inversely correlated with peak oxygen uptake (13). However, the rela-
tion between the V’O2/HR slope and the occurrence of cardiovascular dysfunction due to 
SSc related pulmonary vasculopathy (PV) is unknown. Therefore, this slope may contain 
additional information on the cardiovascular response to exercise in SSc. 
In our clinical experience, a significant number of SSc patients show a V’O2/HR slope with 
a breakpoint during exercise testing while pulmonary pressures measured by DE at rest are 
normal (9). In these patients, the heart rate suddenly increases disproportionally to an in-
crease in V’O2 before reaching the predicted peak oxygen uptake. This response may reflect 
acute increased pulmonary arterial pressures to indicate a change in cardiac response (7;12). 
We therefore hypothesized that the onset of a breakpoint in the V’O2/HR slope is a result of 
a sudden increase in pulmonary arterial pressures. In these patients the exercise capacity 
and oxygen uptake may be decreased and may be related to SPAP at rest.
Methods
Ethics statement
The local Medical Ethical Committee of the Leiden University Medical Center approved the 
protocol. A written informed consent was obtained from each patient prior to enrollment.
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The V’O2/HR breakpoint principle and analysis
Both oxygen uptake (on a breath-by-breath basis) as well as heart rate are recorded continu-
ously during CPET. Both variables are related to each other and therefore may be presented in 
a single graph, resulting into a V’O2/HR slope. In general, several hypothetical V’O2/HR slopes 
(tracks) during CPET may be obtained (Figure 2.1). Patients may either show a monophasic 
or a biphasic V’O2/HR slope (9) characterized by one or two angles, respectively. In patients 
Figure 2.1 Hypothetical V’O2/HR slopes, in which corrected HR values are used. 
Normal V’O2/HR slopes are located in the area defined by highly weighted black tracks: the heart rate has an 
upper and lower limit of 220-age (yr) ± 15 beats/minute, whereas the peak V’O2 has and upper and lower limit 
of predicted V’O2 ± 15% (9). The oxygen pulse isopleths are provided at 5 and 20 ml per beat.
The dotted track in the middle of this area represents the ideal V’O2/HR, whereas the black dot in the square 
box represents the predicted peak oxygen pulse. 
Track 1 represents a steep V’O2/HR slope reflecting low stroke volumes from the start of exercise.
Track 2 represents a V’O2/HR with a breakpoint and a peak oxygen pulse located outside the normal range 
(i.e. pathological oxygen pulse slope). 
Track 3 represents an abnormal V’O2/HR from the start, including a breakpoint and a peak oxygen pulse 
outside the normal range. 
Track 4 represents initially an abnormal V’O2/HR, including a breakpoint, which normalizes as exercise progresses 
(i.e. “nervous anticipation”). 
Track 5 represents a V’O2/HR with a breakpoint and a normal peak oxygen pulse (i.e. V’O2peak = V’O2max)
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showing a biphasic V’O2/HR slope, the heart rate is increasing disproportionally against an 
increase in oxygen uptake when exercise is in progress, and is reflected by a breakpoint. 
This breakpoint represents a change in cardiovascular response to exercise by an abrupt 
increase in heart rate since cardiac output cannot effectively increase by stroke volume alone.
Patients may show a biphasic V’O2/HR slope and a peak V’O2/HR located outside the normal 
range as indicated in Figure 2.1, track 2 and 3. On the other hand, patients may show no 
breakpoint but only a steep V’O2/HR slope completely located outside the normal range 
(Figure 2.1, track 1). Both responses are defined by us as pathologic. 
The analytical problem was to mathematically identify the breakpoint in a biphasic V’O2/
HR slope. Regression lines were calculated between subsequent increases in V’O2 and HR 
to define a breakpoint by applying freely available software for these calculations (example 
Figure 2.2) (14). In this program, a joinpoint (i.e. breakpoint) regression model is applied 
to describe such continuous changes. We used the grid-search method to fit the regression 
function with a predefined number of jointpoints and assumed constant variance and 
uncorrelated errors. As a result, this predefined joinpoint is found by performing several 
permutation tests. Other possible approaches, such as a polynomial fit to the data, could 
Figure 2.2 Example of a mathematically defined breakpoint in a V’O2/HR slope in a single patient (track 
with square dots). 
Grey track represents the actual derived heart rate and V’O2.
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be considered, however, these do not produce a single value for a breakpoint. Therefore we 
adopted the joinpoint method in our analysis. 
Patients
First, we explored the kinetics of V’O2/HR slopes in a historic Austrian dataset of SSc 
patients. Data of some of these patients were described previously (5) and contained SSc 
patients in whom pulmonary artery pressures measured by right heart catheterization 
(RHC) were obtained during CPET. An increase in the pulmonary pressures reflects a 
decreased pulmonary vessel wall compliance resulting in a sudden increase in heart rate 
or right ventricular stroke volume. Therefore, we were not only able to evaluate whether a 
breakpoint in the V’O2/HR slope was present but also if it was related to a change in mPAP 
(i.e. a V’O2/mPAP breakpoint). In these patients, 40 out of 45 patients completed both CPET 
and RHC tests which proved eligible for our analysis. We applied our software for regression 
analysis to calculate a V’O2/HR and V’O2/mPAP breakpoint, respectively (14). Figure 2.3 
shows the disposition of patients.
Secondly, in the Leiden University Medical Center (LUMC) we screened 131 SSc patients 
consecutively referred to an outpatient targeted health care program in a prospective design. 
Patients were classified as limited cutaneous systemic sclerosis (lcSSc) or diffuse cutaneous 
systemic sclerosis (dcSSc) according to the LeRoy criteria (15). All SSc patients underwent 
Doppler echocardiography using a commercially available system (Vingmed Vivid 7 and 
E9, General Electric Vingmed Ultrasound, Horten, Norway). Images were obtained using a 
3.5-Mhz transducer and digitally stored in cine-loop format. Subsequent offline analysis was 
performed using EchoPAC version 110.0.0 (General Electric-Vingmed Ultrasound, Horten, 
Norway). In all patients Doppler envelopes were well developed. SPAP could therefore be 
estimated from the tricuspid regurgitation peak gradient using the Bernoulli equation, 
adding the right atrial pressure estimated by the dimension and the degree of the inferior 
vena cava respiratory collapse (16;17). Patients were considered to have elevated pulmonary 
systolic pressures if SPAP was ≥35 mmHg (17). Furthermore, all patients had laboratory 
testing, pulmonary function testing (PFTs) (18;19), symptom limiting non-invasive CPET 
(6;10;20), six minute walk test (6MWT) and high-resolution CT scan (HRCT). CT scans 
were scored as less or more than 20% involvement of interstitial lung disease (ILD) (21). 
All tests were done in one or two consecutive days. 
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Statistical analysis was performed with the SPSS 20.0 package (SPSS, Inc., Chicago, IL, 
USA). All data were checked for normal distribution. Continuous variables are expressed 
as mean value ± standard deviations. Two-sided p-values <0.05 were considered significant. 
Categorical data are presented as frequencies and percentages. Statistical comparisons were 
performed by using Student’s T-test for continuous variables, and chi square test for binary 
variables. 
Results
Evaluation of the V’O2/HR breakpoint principle in a historic dataset
In 40 out of 45 patients of the historic dataset CPET and RHC data were available and 
suitable for analysis (Figure 2.3). Six patients showed a mixed response in the occurrence 
of breakpoints. In total, 16 out of 34 of these SSc patients (47%) had a breakpoint in both 
V’O2/HR and V’O2/mPAP slopes. The remaining 18 patients had no breakpoint in either 
slope. As an example, Figure 2.4 shows the breakpoint in a V’O2/HR slope and in a V’O2/
mPAP slope during exercise. For each patient we calculated the difference in V’O2 between 
these two breakpoints. Mean difference in V’O2 was 127 ml ± 63 ml. In 15/16 (94%) of these 
patients, the breakpoint in the V’O2/mPAP slope preceded the breakpoint in the V’O2/HR 
slope (i.e. earlier during exercise) (Figure 2.4). Taken together, these data suggest that a 
sudden increase in pulmonary arterial pressures results into a disproportional heart rate 
response to exercise. 
Patient characteristics
Patient characteristics of the prospectively collected data are shown in Table 2.1. Patients 
with left ventricular dysfunction or heart valve disease (n=4), use of beta-receptor blocking 
agents (n=3) or endothelin receptor antagonists (n=3) were excluded from analysis. 
Based on the SPAP measured by DE, SSc patients were stratified into a SPAP below and 
above 35 mmHg (98 and 23 patients respectively, Table 2.1). Both groups did not differ in 
terms of gender, age or BMI. However patients with a SPAP ≥35 mmHg had significantly 
higher NT-proBNP, FVC and transfer factor for carbon monoxide were lower (Table 2.1). 
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Figure 2.3 Flowchart of SSc patient selection from Graz, Austria. 


















Also, more ILD was present in patients with a SPAP ≥35 mmHg (p=0.04). During exercise 
testing, patients with SPAP ≥35 mmHg showed a significant decrease in peak V’O2 and peak 
V’O2/HR, an increase in V’E/V’CO2 and a significant difference in ∆ PetCO2AT- PetCO2start 
(Table 2.2). 
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Figure 2.4 Example of a breakpoint in the V’O2/HR slope (track 1) and in the V’O2/mPAP slope (track 2) 
during exercise from an SSc patient. 
Breakpoint in the V’O2/HR slope occurred at a V’O2 of 840 ml. In the V’O2/mPAP slope the breakpoint occurred 
at a V’O2 of 734 ml.





Gender (female) n (%) 78 (79) 18 (78) 0.89
Age, years 55 ± 14.2 60 ± 15.4 0.097
BMI (kg/m2) 22.8 ± 3.4 21.4 ± 3.1 0.68
lcSSc, n (%) 52 (53) 11 (48) 0.79
Laboratory results
Hb, mmol L-1 8.1 ± 0.7 7.8 ± 0.6 0.09
Pro-BNP 186 ± 345 944 ± 961 <0.001
Doppler echocardiography
SPAP 26.8 ± 4.4 42.4 ± 7.7 <0.001
Pulmonary function test
FVC % pred 96.8 ± 20.9 78.0 ± 21.8 <0.001
DLCOc SB % pred 66.5 ± 16.5 49.3 ± 10.4 <0.001
FVC / DLCO 1.49 ± 0.39 1.59 ± 0.37 0.26
TLC-He % pred 88.9 ± 17.1 73.9 ± 17.5 <0.001
HRCT thorax
>20% extent of disease, n (%) 24 (24) 9 (39) 0.04
BMI, Body mass index; lcSSc, limited systemic sclerosis; Hb, Hemoglobin; pro-BNP, pro-brain natriuretic 
peptide; SPAP, systolic pulmonary arterial pressure; FVC, forced vital capacity; DLCOc SB, diffusion capacity for 
carbon monoxide single breath; TLC-He, total lung capacity, Helium dilution method; HRCT, high-resolution 
computed tomography.
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The V’O2/HR breakpoint principle and analysis  
In the prospectively designed study in LUMC SSc patients with a breakpoint in the V’O2/
HR slope had a significant lower peak V’O2% predicted compared to patients without a 
breakpoint (Table 2.3, p=0.036). Disease duration did not differ between these groups. 
Pathologic slopes classified 41/121 patients (34%, Table 2.3). Classified by a V’O2/HR 
breakpoint, patients with and without a pathologic V’O2/HR slope differed significantly in 
6MWD (p=0.015 and p=0.005). 
Of 23 LUMC patients with a SPAP ≥35 mmHg, 14 had a pathologic V’O2/HR slope (61%). 
Furthermore, mean SPAP differed significantly between patients with and without a 
pathologic V’O2/HR (31.8 vs. 28.2 mmHg, respectively, p=0.027). Importantly, of 98 LUMC 
SSc patients 27 (28%) had a pathologic V’O2/HR slope not expected by SPAP at rest (resting 
SPAP <35 mmHg).






Peak V’O2 (% pred) 88 ± 22 70 ± 19 0.001
AT (% peak V’O2) 43 ± 14 38 ± 7 0.14
RER 1.18 ± 0.12 1.18 ± 0.11 0.95
Cardiac function
Peak O2-pulse (% pred) 97 ± 25 72 ± 21 0.006
∆V’O2/∆WR (ml/min/W) 9.1 ± 1.9 8.6 ± 2.0 0.56
HRR 14.6 ± 20.6 10.7 ± 14.6 0.29
Ventilatory efficiency
V’E/V’CO2AT 31.5 ± 4.4 35.7 ± 4.5 <0.001
PetCO2AT (mmHg) 35.9 ± 3.79 33.7 ± 5.0 0.025
∆PetCO2AT- PetCO2start (mmHg) 4.17 ± 2.2 1.4 ± 1.9 0.002
Peak V’O2, peak oxygen uptake; AT, anaerobic threshold; RER, respiratory exchange ratio; peak O2-pulse, peak 
oxygen pulse; ∆V’O2/∆WR, oxygen uptake against work rate; HRR, heart rate reserve; V’E/V’CO2AT, ventilatory 
equivalent for carbon dioxide at anaerobic threshold; PetCO2AT, end-tidal carbon dioxide tension.
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We report a novel analysis of the V’O2/HR slope to exercise in the clinical evaluation of 
systemic sclerosis patients which showed that a breakpoint in the V’O2/HR slope is preceded 
by a breakpoint in the slope of pulmonary arterial pressures against oxygen uptake. This 
suggests that the increase in pulmonary pressures results in a change in heart rate response 
to maintain sufficient cardiac output. In patients with a breakpoint in the V’O2/HR slope, 
peak oxygen uptake was limited and differed significantly compared to patients without a 
breakpoint. Importantly, in patients with normal SPAP at rest, non-invasive CPET identified 
patients with a V’O2/HR slope not fitting in the normal range (i.e. pathologic V’O2/HR 
slope). In the evaluation of SSc patients, analysis of the V’O2/HR slope may therefore 
reveal important information extending that of resting Doppler echocardiography. Taken 
together, these patients may be at risk for developing pulmonary vasculopathy and ultimately 
pulmonary hypertension. 
Since SSc patients may develop PH in their course of the disease, early detection and careful 
monitoring are warranted (22). Previously, Doppler echocardiography and right heart 
catheterization have been evaluated to estimate or measure elevated pulmonary arterial 
pressures at rest (3;8;17;23). Stress Doppler echocardiography has been recently studied 
longitudinally and an increase of 18 mmHg during exercise was found to correspond with a 










Peak V’O2 (% pred) 81 90 0.036
SPAP (mmHg) 30 29 0.52















Peak V’O2 (% pred) 57 92 <0.001 79 108 <0.001
SPAP (mmHg) 32 28 0.10 31 28 0.12
6MWD (m) 413 515 0.015 489 587 0.005
Peak V’O2, peak oxygen uptake (ml/min); SPAP, systolic pulmonary artery pressure; 6MWD, 6 minute walking 
distance.
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sensitivity of 50% and a specificity of 90% of developing PH during follow-up (24). However, 
disadvantages of this technique include patient and operator dependent issues, such as 
evaluating exercise echocardiography images. Non-invasive CPET is another important tool 
in the evaluation of PH. Analysis of various gas exchange and cardiocirculatory parameters 
such as oxygen uptake is feasible and can be easily interpreted. Therefore we focused on 
additional analysis of these cardiocirculatory parameters during exercise.
In our clinical experience, SSc patients may display a breakpoint in the V’O2/HR slope during 
exercise. In these patients, cardiac output cannot effectively increase by stroke volume alone. 
In general, in patients with increasing pulmonary pressures during exercise, heart rate increase 
is the main mechanism for increasing cardiac output. This results in a significantly steeper 
slope of V’O2/HR (25-27), which may contain a breakpoint at which the heart rate “takes 
off ” (e.g. Figure 2.1, track 2) (6;9;10). To confirm that these responses are also present in 
SSc patients, we applied our slope analysis to a historic dataset in which exercise testing and 
right heart catheterization were done simultaneously. We found that a sudden increase in 
the pulmonary pressures results in a disproportional sudden increase in HR during exercise. 
Since the occurrence of a breakpoint in a V’O2/HR slope may vary during exercise and 
reflects a sudden change in the pulmonary vasculature, it may be the result of a reduced 
compliance of the pulmonary vasculature. Indeed, the pulmonary vasculature in SSc may 
be affected by progressive obliteration of microvascular structures resulting into a reduced 
compliance (1;4). When the pulmonary vascular resistance (PVR) is abnormally increased 
during exercise, or does not decrease appropriately, right ventricular function can become 
compromised (28). In patients with exercise induced pulmonary hypertension (EIPAH), 
two different groups were defined by the nature of their mPAP response to exercise (2;28). 
Data during exercise were analyzed using best-fit two-segment plots of mPAP versus oxygen 
uptake. Patients with severe EIPAH and resting PAH showed a “plateau” physiology (2). In 
these patients mPAP will increase as well as PVR during exercise until the cardiac output 
is compromised and starts to fall. Eventually, with a decline in cardiac output as a result 
of right ventricular dysfunction, PAP will not further increase or even fall resulting in a 
compensatory tachycardia. In contrast, patients with mild to moderate EIPAH showed a 
“take-off ” physiology, suggesting pulmonary vasoconstriction during incremental exercise 
(2;28). In these patients, mPAP further increases in which the cardiac output does not 
decrease. Therefore, it seems plausible that patients with PAH of varying duration and 
severity will exhibit different mPAP responses to exercise. Likewise, different comparable 
V’O2/HR slopes may be expected in these patients.  
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In SSc pulmonary vascular remodeling occurs and may progress into pulmonary 
vasculopathy and pulmonary hypertension (29). Intimal proliferation, decreased compliance 
and increased elastance of the pulmonary vasculature may cause a “take-off ” physiology. 
Indeed, 15 Austrian patients showed a “take-off ” pattern and none a “plateau” pattern. 
Mean PAP in these patients measured at 50 Watts and at maximum exercise corresponded 
well to reported values in other patients with a “take-off ” physiology (2;28). Therefore, 
these pressures may represent an intermediate stage between a physiologic response and 
manifest PAH (29). Furthermore, in these patients sudden increases in pulmonary pressures 
during exercise were followed by sudden increases in heart rate against oxygen uptake. Since 
different mPAP responses in patients with varying PAH or EIPAH are present, different 
V’O2/HR responses are likely to occur. In other words, pulmonary vasculopathy, as reflected 
by a sudden increase in pulmonary pressures, may result into a breakpoint in the V’O2/HR 
slope during non-invasive CPET. Consequently, the pulmonary vasculature may be more 
affected in patients showing a pathologic V’O2/HR slope compared to patients without a 
pathologic V’O2/HR slope. Mean SPAP was significantly different between these groups 
(Table 2.3). Likewise, in patients showing a breakpoint in the V’O2/HR slope, predicted 
peak oxygen uptake (V’O2% predicted) was significantly lower than in patients without a 
V’O2/HR breakpoint (Table 2.3) indicating the importance of the V’O2/HR slope analysis. 
Concerning the occurrence of a breakpoint in the V’O2/HR slope, some clarifications are 
important. First, in the absence of anemia, carboxyhemoglobinemia, poor blood oxygenation 
in the lung, right-to-left shunt or low peripheral oxygen extraction, a breakpoint in the 
V’O2/HR slope may reflect an impaired cardiovascular response (7;9). However, in all 
these responses, a normal peak V’O2 may still be achieved. Furthermore, in some subjects, 
a breakpoint due to “nervous anticipation” to exercise is observed (Figure 2.1, track 4) or 
when V’O2 is approaching V’O2max (Figure 2.1, track 5). These latter responses to exercise 
are considered by us the only physiological exceptions when a V’O2/HR slope contains a 
breakpoint (9). Secondly, in patients displaying a pathologic V’O2/HR slope, a V’O2/HR 
breakpoint may not always be present. Moreover, their V’O2 slope may be steep from start of 
exercise (e.g. Figure 2.1, track 1). Nevertheless, pulmonary hypertension at rest may develop 
in the course of their disease. In contrast, patients may display a pathologic V’O2/HR slope 
with a breakpoint (e.g. Figure 2.1, track 2). The latter response, however, is considered by 
us less pathologic since the slope starts less steep and peak V’O2 approaches the predicted 
value more closely. Thirdly, in the LUMC dataset a decrease or a less than normal increase 
in end-tidal pCO2 (∆PetCO2AT-PetCO2start, Table 2.2) was present in some of these patients, 
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which may reflect hypoperfusion in well-ventilated acini (6). Fourthly, none of our patients 
showed an oxygen desaturation during CPET as measured by pulse oximetry. Therefore, 
reduced peripheral oxygen extraction as a cause of the pathological V’O2/HR slope was not 
likely in the LUMC patients. Finally, in the present study, 9 patients with a SPAP ≥35 mmHg 
and 24 patients with a SPAP <35 mmHg had ≥20% involvement of ILD on their HRCT 
according to the classification of Goh et al (21). However, in both groups breakpoints in the 
V’O2/HR slopes did not influence peak oxygen uptake nor pathologic V’O2/HR slopes were 
observed (data not shown). Therefore, the reduced peak oxygen uptake and pathologic V’O2/
HR slopes were considered to reflect changes in the pulmonary vasculature during exercise. 
We conclude that our novel analysis of the V’O2/HR slope showed that SSc patients with a 
breakpoint in this slope are characterized by a decreased oxygen uptake and exercise capacity. 
This breakpoint is preceded by a sudden increase in pulmonary arterial pressures and may 
therefore reflect an inadequate increase or even decrease in stroke volumes. Importantly, 
non-invasive CPET identified patients with a pathologic V’O2/HR slope despite normal 
echocardiographic pulmonary pressures at rest. These patients may have a compromised 
pulmonary vasculature and are at risk for developing pulmonary vasculopathy and ultimately 
pulmonary hypertension. To assess the predictive value of the V’O2/HR breakpoint analysis, 
we currently perform serial CPET and echocardiography in patients with normal SPAP and 
a pathologic V’O2/HR slope or with a V’O2/HR breakpoint. Our results imply that analysis 
of the V’O2/HR slope is warranted in every newly diagnosed SSc patient. In addition, since 
a compromised pulmonary vasculature is not restricted to systemic sclerosis, our novel 
analysis may also be applicable to other types of lung disease coinciding with cardiovascular 
malfunction. 
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Background: Systemic sclerosis is a connective tissue disease characterized by vascular 
inflammation and fibrosis. Visceral involvement, including cardiac manifestations can lead 
to severe clinical complications, such as congestive heart failure, arrhythmias and sudden 
death. Conventional echocardiography parameters have limited sensitivity to detect subtle 
myocardial dysfunction in patients with systemic sclerosis (SSc). The aim of the study was to 
assess, using novel speckle tracking strain analysis, the presence of myocardial dysfunction 
in SSc patients and to investigate its relationship with functional capacity and ventricular 
arrhythmias. 
Methods: A total of 104 SSc patients (age 54±11 yrs, 77% female) were included and 
underwent cardiopulmonary exercise testing, 24-hour electrocardiography Holter, and 
transthoracic echocardiography. For comparison purposes, 37 matched healthy controls 
were included. 
Results: The total population consisted of 51 patients with limited SSc and 53 patients 
with diffuse SSc. Peak VO2% predicted was 91±20% and 28 patients had abnormal Holter 
findings (ventricular tachycardia or ventricular ectopics >100/day). Patients with SSc have 
impaired global longitudinal (-18.2±1.8%) and circumferential strains (-18.2±2.3%) as 
compared to controls (21.3±1.7%, p<0.01, p<0.01 respectively), but not left ventricular 
ejection fraction (63.5±7.2% vs 64.6±4.4%, p=0.20). In patients with SSc, global longitudinal 
(r=-0.46, p<0.01) and circumferential strains (r=-0.41, p<0.01) correlated with peak VO2% 
predicted. Multivariate analysis showed that global longitudinal and circumferential strains 
were independently associated with peak VO2% predicted. Patients with abnormal Holter 
findings showed impaired global longitudinal (-18.5±1.5 vs -17.1±2.1%, p<0.01) and 
circumferential (-18.7±2.0 vs -17.3±2.5%, p=0.01) strains as compared to controls, and were 
independently associated with abnormal Holter findings.  
Conclusion: Speckle tracking strain analysis detected subtle myocardial dysfunction in 
SSc patients. Importantly, decreased global longitudinal and circumferential strains are 
associated with lower functional capacity and rhythm disturbances.  
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Systemic sclerosis (SSc) is an autoimmune disease characterized by deposition of collagen 
in multiple organs and associated with significant disability and reduced life expectancy 
(1). Cardiovascular involvement has been shown to be one of the leading causes of mortal-
ity in SSc (2) and to occur in up to 70% of patients as autoptic finding (3). Early diagnosis 
and accurate staging of myocardial involvement are therefore crucial for the management 
of these patients and for therapeutic strategies. 
Conventional echocardiographic assessment of left ventricular (LV) systolic function is 
based on the measure of LV ejection fraction (EF). This approach however showed limited 
sensitivity for the assessment of myocardial abnormalities in SSc patients, being able to 
identify only 5% of patients with cardiac involvement (4). More sophisticated and sensitive 
techniques for the assessment of LV function are therefore needed to improve the detection 
of subclinical myocardial dysfunction in SSc patients. Initial studies using tissue Doppler 
imaging suggested that myocardial velocity and deformation (strain) might be more sensi-
tive than conventional measures in identifying subtle cardiac dysfunction in asymptomatic 
SSc patients (5-7). However, the clinical implications of this alternative approach for LV 
function assessment have not been evaluated.
Recently, two-dimensional (2D) speckle tracking analysis has been proposed as a sensitive 
and accurate method for the evaluation of subclinical myocardial dysfunction, providing 
measures of LV regional and global strain in three orthogonal directions (longitudinal, 
circumferential and radial) (8). The aim of this study was therefore to apply this novel 
technique to assess the presence of LV systolic dysfunction in a large cohort of SSc patients. 
Furthermore, the clinical value of the measure of LV global strain by 2D speckle tracking 
analysis was evaluated in relation with functional capacity and ventricular arrhythmias.
Methods
Patient population and protocol
The current study included 113 consecutive patients with SSc referred to the department 
of Rheumatology, Leiden University Medical Center. The patients were recruited from two 
studies; a randomized controlled trial evaluating the effectiveness of a multidisciplinary 
team care program (9) and a study evaluating the outcomes of a two-days diagnostic 
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multidisciplinary daycare program (10). All patients underwent an extensive screening, 
including detailed physical examination, a Modified Rodnan Skin Score assessment 
(11), laboratory testing (including erythrocyte sedimentation rate, anti-nuclear, anti-
topoisomerase I, anti-RNP and anti-centromere antibodies assessments), chest X-ray and 
lung function test. Interstitial lung disease was diagnosed by chest X-ray and by lung function 
test, and with computed tomography scan when indicated. Patients were classified as limited 
systemic sclerosis (lSSc) or diffuse systemic sclerosis (dSSc), according to the classification 
system described by LeRoy et al. (12) In addition, cardiopulmonary exercise (CPET) and 
24-hour electrocardiography (ECG) Holter monitoring were performed to assess patient 
functional capacity and potential ventricular arrhythmias, respectively. All patients had no 
angina pectoris or symptoms attributable to cardiovascular disease and therefore specific 
tests for microvascular and macrovascular ischemia were not performed. Transthoracic 
echocardiography was performed to evaluate conventional parameters of cardiac function 
and to assess subclinical LV systolic dysfunction using novel speckle tracking analysis. 
The relationship of LV function with functional capacity and ventricular arrhythmias was 
evaluated.
Seven patients were not able to perform CPET (because of severe pulmonary hypertension in 
4 patients, severe aortic valve stenosis in 1 patient and severe SSc disease status in 2 patients) 
and therefore excluded from the analysis. In addition, 2 patients were excluded because of 
an incomplete clinical assessment. The final study population consisted of 104 patients. 
For comparison purposes, 37 normal individuals (1:3 ratio with SSc patients) matched for 
age and gender were included as a control group. These subjects were referred for atypical 
chest pain, palpitations, or syncope without murmur and showed normal structural heart 
on echocardiography. 
The study protocol was approved by the Ethics Committee of the Leiden University Medical 
Center. All participants provided written informed consent for the studies in which they 
participated
Lung function test
Lung function test was performed in all SSc patients and included spirometry and single 
breath diffusion lung capacity for carbon monoxide (DLCO). Spirometry measurements 
included forced vital capacity (FVC) and total lung capacity (TLC) measured according to 
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the American Thoracic Society/European Respiratory Society recommendations (13-15) 
and expressed as percentage predicted.
Conventional echocardiography
All SSc patients and controls were imaged in the left lateral decubitus position using a 
commercially available system (Vingmed Vivid 7, General Electric Vingmed Ultrasound, 
Milwaukee, USA). Images were obtained using a 3.5-MHz transducer and digitally stored in 
cine-loop format; offline analysis was performed using EchoPAC version 108.1.5 (General 
Electric – Vingmed, Horten, Norway). LV dimensions, volumes and EF were measured 
according to the current recommendations (16). Evaluation of LV diastolic function was 
based on the pulsed-wave Doppler of mitral valve inflow as recommended by the American 
Society of Echocardiography (17), measuring peak early diastolic velocity (E), peak late 
(A) diastolic velocity, their ratio (E/A) and the E wave deceleration. Pulmonary venous 
flow velocities during systole (S) and diastole (D) were also recorded. Using tissue Doppler 
imaging, the early diastolic velocity (E`) and systolic velocity (S`) was measured at the level 
of the LV basal lateral segment. In addition, E/E` ratio was calculated as an estimation of 
LV filling pressure (18). LV diastolic dysfunction was therefore categorized as previously 
described: normal; mild, defined as LV impaired relaxation without evidence of increased 
filling pressure; moderate, defined as LV impaired relaxation associated with moderate 
elevation of filling pressures or pseudo-normal filling; and severe, defined as restrictive LV 
filling (17). Pulmonary arterial systolic pressure (PASP) was estimated by right ventricular 
systolic pressure, which was calculated from the tricuspid regurgitation peak gradient using 
Bernoulli equation, and adding right atrial pressure estimated by the dimension and the 
degree of inferior vena cava respiratory collapse (19). 
Two-dimensional speckle tracking strain analysis
Two-dimensional speckle tracking analysis is a novel imaging technique which allows the 
assessment of LV myocardial deformation by tracking natural acoustic markers (speckles) 
in a frame-to-frame basis within the cardiac cycle. The speckles are visible in the standard 
gray-scale 2D images and are equally distributed within the myocardium. As represented in 
Figure 3.1, LV deformation can be assessed in three orthogonal directions as longitudinal, 
circumferential and radial strain (20). 
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Longitudinal strain, evaluating the shortening/lengthening of the myocardial wall, was 
measured from the 3 apical views: 2-chamber view (including anterior and inferior walls), 
4-chamber view (posteroseptal and lateral walls) and long axis view (anteroseptal and 
posterior walls). Each wall was divided into 3 levels (basal, mid and apical) and subsequently 
18 segmental strain curves were obtained. Global longitudinal strain was calculated as the 
average of peak systolic strain values of the 18 segments (Figure 3.2a). 
From LV mid-ventricular short-axis view, circumferential strain (evaluating myocardial 
shortening/lengthening along LV curvature) and radial strain (evaluating myocardial 
thickening/thinning) were measured. The global values of circumferential and radial strains 
were derived from the average of peak systolic strain values of 6 segments, as illustrated 
in Figure 3.2b and 3.2c, respectively. Global longitudinal and circumferential strains are 
expressed as negative values, and a lower strain is represented by less negative values. Global 
radial strain is expressed as positive values, and lower values indicate lower strain.
The intra- and inter-observer agreement for the measurements of longitudinal, circum-
ferential and radial strains have been reported previously (20). 
Figure 3.1 Schematic representations of the three orthogonal directions of strain measured with two-
dimensional speckle tracking analysis. 
Global longitudinal strain evaluates the shortening/lengthening of the myocardial wall. Radial strain evaluates 
the thickening and thinning of the myocardial wall and circumferential strain asses the shortening/lengthening 
along the curvature of the LV.
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Cardiopulmonary exercise testing 
All SSc patients performed a maximal exercise stress test on an electrically braked stationary 
cycle ergometer using a ramp protocol according to the American Thoracic Society/
American College of Chest Physician statement on cardiopulmonary testing (21). Briefly, 
a tight fitting facemask was worn by the patients and allowed ventilation and metabolic gas 
exchange measurements (Oxycon Pro, Jaeger-Viasys Healthcare, Hoechberg, Germany). 
The initial work load was 30W, with further increment of 5W every 30 seconds. Patients 
were encouraged to exercise until exhaustion or until supervising physician stopped the test 
because of significant symptoms, such as chest pain, dizziness, ST-segment deviations, or 
marked systolic hypotension or hypertension. Peak VO2 was defined as the highest oxygen 
consumption during any stage of maximal exercise. Furthermore, peak VO2 was adjusted 
to age, gender and weight and expressed as percentage predicted. 
24-hour electrocardiography Holter monitoring
A 24-hour ECG Holter monitoring was performed in 100 out of 104 patients to detect 
potential ventricular arrhythmias. Abnormal Holter results were defined as the presence of 
intermittent bundle branch block, ventricular arrhythmias including frequent monomorphic 
and/or polymorphic premature ventricular contractions >100 per day, or non-sustained or 
sustained ventricular tachycardia (22). 
Statistical analysis
Continuous variables are presented as mean ± standard deviation. Categorical data are 
presented as frequencies and percentages. Continuous variables were tested for normal 
distribution with the Kolmogorov-Smirnov test. Statistical comparisons were performed 
by using Student’s t test for continuous variables, and chi square test for binary variables. 
Univariate linear regression analysis was used to identify potential determinants of peak 
VO2% predicted. Correlations were expressed in terms of Pearson’s correlation coefficient. 
Moreover, univariate binary logistic regression was used to determine the factors associated 
(using odd ratios (OR) and confidence intervals (CI)) with abnormal Holter results. The 
final multivariate models for peak VO2% predicted and abnormal Holter results were 
obtained using the enter method by including parameters that were statistically significant 
in univariate analysis. To avoid bias from multicollinearity, multi-directional global strains 
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were entered to the step-wise model individually. ANCOVA tests with covariates to correct 
for significant different variables of subpopulation characteristics were performed. All 
statistical analysis were performed using the statistical package SPSS for windows (Version 
15.0, SPSS, Chicago, USA). A p-value <0.05 was considered to be statistically significant.   
Results
Clinical characteristics of the patient population
A total of 51 (49%) patients were classified as having lSSc and 53 (51%) patients as having 
dSSc. Clinical characteristics of the total population and of the 2 subtypes of SSc (limited and 
diffuse) are shown in Table 3.1. According to the matching criteria, age (54±10 vs. 54±12, 
p=0.82) and gender (female 77% vs. 73%, p=0.66) were similar between SSc patients and 
controls. Most of SSc patients were positive for antinuclear antibodies and approximately 
50% had underlying interstitial lung disease. In addition, 24 patients (20 dSSc patients and 
4 lSSc patients) received a treatment with cyclophosphamide, and 13 patients (all dSSC) 
stem cell transplantation. A total of 4 patients had mild pulmonary hypertension (2 due to 
underlying interstitial lung disease and 2 due to pulmonary arterial hypertension), 1 patient 
had a previous myocardial infarction and 2 patients were known for epicardial coronary 
artery disease.
Patients with dSSc were associated with a younger age, shorter time since diagnosis and 
time since onset of Raynaud’s phenomenon and skin manifestation. Moreover, patients with 
dSSc were more likely to have underlying interstitial lung disease, lower TLC% predicted 
and to receive angiotensin-converting enzyme inhibitors (mainly to prevent renal crisis) as 
compared to patients with lSSc. Patients with lSSc had a significantly lower prevalence of 
anti-topoisomerase antibodies and a lower modified Rodnan skin score.
Echocardiographic characteristics of the patient population
Conventional echocardiographic parameters of LV systolic and diastolic function of SSc 
patients and controls are shown in Table 3.2. No significant differences were noted in 
LV volumes and EF between SSc patients and controls (Table 3.2). Moreover, S` velocity 
derived from tissue Doppler imaging was similar to controls. However, estimated PASP was 
significantly higher in SSc patients as compared to controls and E/E` ratio and LV diastolic 
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Table 3.1 Clinical characteristics of the 104 patients with systemic sclerosis (SSc) and comparison between 
patients with limited systemic sclerosis (lSSc) and diffuse systemic sclerosis (dSSc)
SSc (n=104) lSSc (n=51) dSSc (n=53) p-value
Age (yrs) 54±12 58±12 50±12 <0.01
Female gender, n (%) 80 (77) 43 (84) 37 (70) 0.08
Time since diagnosis, yrs 5.1±2.3 7.1±3.5 4.1±2.5 <0.01
Time since onset of Raynaud’s, yrs 8.6±6.3 15.0±5.8 5.8±4.2 <0.01
Time since onset of skin manifestation, yrs 5.6 ±3.5 7.1 ±6.2 4.7 ±2.8 0.02
Modified Rodnan Skin Score 5.6±6.1 2.8±2.2 8.3±7.4 <0.01
Systolic blood pressure, mmHg 122±18 125±18 119±18 0.08
Diastolic blood pressure, mmHg 71±9 70±8 72±11 0.23
Systemic hypertension 11 (11) 2 (18) 9 (82) 0.03
ESR, mm/hr 20.5±17.6 20.7±19.8 20.3±15.4 0.91
Immune markers
Anti-nuclear, n (%) 94 (90) 46 (90) 48 (91) 0.61
Anti-topoisomerase, n (%) 36 (35) 7 (14) 29 (58) <0.01
Anti-centromere, n (%) 25 (24) 21 (41) 4 (7) <0.01
Anti-RNP, n (%) 7 (7) 5 (10) 2 (4) 0.38
Interstitial lung disease, n (%) 49 (47) 15 (28) 34 (64) <0.01
Pulmonary hypertension 4 (4) 1 (2) 3 (6) 0.62
*Chronic kidney disease 10 (10) 6 (12) 4 (8) 0.52
Lung function
FVC% predicted 94.4±14.4 94.9±12.4 93.9±15.9 0.73
TLC% predicted 86.9±18.1 92.7±17.2 82.1±17.5 <0.01
DLCO% predicted 63.3±16.8 65.4±17.5 61.2±16.1 0.22
Current immunosuppressive medication (%)
Corticosteroids, n (%) 15 (14) 6 (12) 9 (17) 0.45
Methotrexate, n (%) 4 (8) 3 (6) 4 (8) 0.52
Azathioprine, n (%) 2 (4) 4 (8) 2 (4) 0.32
Current cardiovascular medications (%)
Calcium antagonists, n (%) 46 (44) 17 (33) 29 (55) 0.03
ACE inhibitors, n (%) 42 (40) 12 (24) 30 (57) <0.01
ACE, Angiotensin converting-enzyme; dSSc, Diffuse systemic sclerosis; DLCO, Diffusion lung capacity for 
carbon monoxide; ESR, Erythrocyte sedimentation rate; FVC, Forced vital capacity; TLC, Total lung capacity.
* Chronic kidney disease defined as an estimated glomerular filtration clearance rate <60 ml/min/1.73m2 for 
more than 3 months.
dysfunction grade were significantly worse. When comparing the 2 different subtypes of 
SSc, both groups showed similar values of conventional echocardiographic parameters.
In order to detect subtle LV dysfunction, myocardial strain values in three orthogonal 
directions were measured by speckle tracking analysis (Table 3.2). Both global longitudinal 
and circumferential strains were significantly impaired in SSc patients as compared to 
controls. However, no difference was noted in global radial strain between SSc patients 
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and normal subjects. Of note, dSSc patients showed worse values of global longitudinal and 
circumferential strain as compared to lSSc patients.
Table 3.2 Conventional echocardiographic parameters and two-dimensional speckle tracking strain 
measurements in patients with systemic sclerosis (SSc) versus controls and in patients with limited (lSSc) 










LV end diastolic volume (ml) 70.6±20.6 76.0±25.4 0.21 72.9±22.4 78.9±23.0 0.24
LV end systolic volume (ml) 26.6±5.7 29.1±13.1 0.13 28.8±13.9 29.4±12.5 0.82
LV ejection fraction (%) 64.6±4.4 63.5±7.2 0.20 64.6±7.9 63.4±6.4 0.19
PASP (mmHg) 21.7±6.3 28.9±8.7 <0.01 29.5±8.3 28.3±9.1 0.48
LV diastolic function, n (%)
Normal 21 (62) 35 (34) <0.01 18 (35) 17 (32) 0.62
Mild 9 (24) 24 (23) 12 (24) 12 (23)
Moderate 5 (14) 30 (29) 16 (31) 14 (26)
Severe 0 (0) 15 (14) 5 (10) 10 (19)
E` velocity (cm/s) 9.8±2.0 8.5±2.8 0.03 8.8±2.7 8.1±3.0 0.22
E/E` ratio 7.7±1.9 10.1±3.8 <0.01 10.2±3.8 10.0±3.7 0.73
S` velocity (cm/s) 6.4±1.4 6.3±2.1 0.81 6.8±2.0 5.7±2.0 <0.01
Speckle tracking analysis
Global longitudinal strain (%) -21.3±1.7 -18.2±1.8 <0.01 -18.6±1.6 -17.9±1.9 0.02
Global circumferential strain (%) -21.3±2.1 -18.2±2.3 <0.01 -19.0±2.0 -17.5±2.3 <0.01
Global radial strain (%) 40.3±12.4 37.0±13.9 0.18 37.6±13.1 36.3±14.7 0.65
LV, Left ventricular; PASP, Pulmonary arterial systolic pressure; E, Early; A, Late; E`, Early diastolic velocity at 
basal mitral annulus; for other abbreviations, see Table 3.1.
Cardiopulmonary exercise testing
All SSc patients completed the CPET with at least 50W exercise level and reached anaerobic 
threshold, the heart rate recovery (HRR) was >12 beats/minute and a respiratory exchange 
ratio >1.00, suggesting a satisfactory exercise capacity in the study population. The mean 
peak VO2% predicted was 90.6±20.4% and the maximum exercise time was 9.9±3.6 min 
suggesting a relatively preserved functional capacity in the population. Patients with dSSc 
had a significantly lower peak VO2% predicted compared to those with lSSc (83.2±21.1 vs. 
99.7±24.7%, p<0.01). 
According to Pearson’s correlation analysis, peak VO2% predicted was not related to 
conventional echocardiographic parameters including LV dimensions, LVEF and LV 
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diastolic function (p>0.05). However, peak VO2% predicted was significantly related to 
global longitudinal (r=-0.46, p<0.01), circumferential (r=-0.41, p<0.01) and radial (r=0.20, 
p=0.05) strains (Figure 3.3). 
Univariate analysis revealed that among all the clinical and echocardiographic characteristics, 
age (β=0.24, Confidence interval [CI] = 0.09–0.83, p=0.02), subtype dSSc (β=0.40, CI=0.30–
0.79, p<0.01), underlying interstitial lung disease (β=0.24, CI=2.23–20.6, p=0.02), TLC% 
predicted (β=0.40, CI=0.30–0.79, p<0.01) and DLCO% predicted (β=0.49, CI=0.46–0.96, 
p<0.01) were significantly associated with peak VO2% predicted. Strain measurements were 
adjusted with the aforementioned parameters in a multivariate analysis, which demonstrated 
that global longitudinal (β=-0.36, CI=-2.72–-7.25, p<0.01) and circumferential (β=-0.34, 
CI=-1.77–-5.47, p<0.01) strains were independently associated with peak VO2% predicted, 
together with age and DLCO%. 
24-hour ECG Holter monitoring
Among the 100 SSc patients who underwent 24-hour ECG Holter monitoring, 28 (28%) 
patients had abnormal results. In particular, 9 patients presented with non-sustained 
ventricular tachycardia and 19 patients had ventricular ectopic >100 per day. 
Clinical and echocardiographic parameters differences between patients with or without 
abnormal Holter results are shown in Table 3.3. Patients with abnormal Holter results were 
more likely to be male and with underlying interstitial lung disease. Conventional LV systolic 
function, LV diastolic dysfunction grade, and S` velocity were similar between patients with 
or without abnormal Holter results. However, E/E` ratio was significantly higher in patients 
with abnormal Holter results. Moreover, global longitudinal and circumferential strains, but 
not global radial strain, were significantly impaired in patients with abnormal Holter results.
Univariate analysis demonstrated that the presence of abnormal Holter results was associated 
with male gender (OR=2.94, CI=1.12–7.69, p<0.01), interstitial lung disease (OR=3.32, 
CI=1.32–8.36, p<0.01), higher E/E` ratio (OR=1.15, CI=1.02–1.32, p=0.04), and lower 
values of global longitudinal (OR=1.71, CI=1.24–2.38, p<0.01) and circumferential strains 
(OR=1.55, CI=1.18–2.03, p<0.01). After multivariate adjustment, both global longitudinal 
(OR=1.47, CI=1.05–2.07, p=0.03) and circumferential (OR=1.35, CI=1.01–1.82, p=0.04) 
strains remained the only independent predictors of abnormal Holter results in SSc patients.
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Figure 3.3 Correlation between peak VO2% predicted and global longitudinal (Panel A), circumferential 
(Panel B) and radial (Panel C) strain measured by two-dimensional speckle tracking analysis. 
Dashed lines correspond to 95% confidence interval.




The results of the current study demonstrated that patients with SSc present subtle LV systolic 
dysfunction, as assessed by 2D speckle tracking strain analysis, despite normal LVEF and 
dimensions. More importantly, LV global longitudinal and circumferential strains, but not 
Table 3.3 Clinical and echocardiographic characteristics of systemic sclerosis patients with and without 






Age, yrs 54±13 56±12 0.45
Female gender, n (%) 59 (81.9) 17 (60.7) 0.04
Interstitial lung disease, n (%) 9 (32.1) 19 (67.9) 0.01
Diffuse systemic sclerosis, n (%) 35 (48.6) 19 (67.9) 0.12
Modified Rodnan Skin Score 5.1±5.8 7.2±7.1 0.16
Immune markers
Anti-nuclear, n (%) 65 (90.3) 26 (92.9) 1.00
Anti-topoisomerase, n (%) 22 (31.4) 13 (46.4) 0.17
Anti-centromere, n (%) 17 (26.2) 7 (25) 1.00
Anti-RNP, n (%) 6 (8.6) 1 (3.6) 0.67
Lung function
FVC% predicted 89.0±17.8 83.2±18.5 0.17
TLC% predicted 64.6±17.2 60.4±16.1 0.25
DLCO% predicted 95.4±13.7 93.6±15.0 0.58
Conventional echocardiographic parameters
LV end diastolic volume, ml 73.5±22.4 79.4±28.7 0.34
LV end systolic volume, ml 27.5±9.9 32.1±18.8 0.23
LV ejection fraction, % 63.9±6.6 62.8±9.1 0.57
PASP, mmHg 28.0±7.5 30.1±10.2 0.36
LV diastolic function, n (%)
Normal 26 (36) 8 (29) 0.36
Mild 17 (24) 5 (18)
Moderate 21 (29) 8 (29)
Severe 8 (11) 7 (25)
E` velocity, cm/s 8.6±2.9 8.1±2.6 0.35
E/E` ratio 9.4±3.8 11.7±4.0 0.04
S` velocity, cm/s 6.3±2.0 6.2±2.2 0.79
Speckle tracking analysis
Global longitudinal strain, % -18.5±1.5 -17.1±2.1 <0.01
Global circumferential strain, % -18.7±2.0 -17.3±2.5 0.01
Global radial strain, % 37.8±14.0 33.7±13.1 0.17
Abbreviations: see Table 3.1 and 3.2.
Chapter_3_Maarten.indd   58 26-10-2015   11:35:48
LV dysfunction assessed by speckle-tracking strain analysis in SSc patients
59
3
conventional echocardiographic parameters, were independently associated with functional 
capacity assessed by CPET, and ventricular arrhythmias detected by 24-hour ECG Holter 
monitoring. 
Cardiac involvement in patients with SSc has been mainly described by the presence of 
elevated PASP and LV diastolic dysfunction (5;6). Recent studies (5-7) using tissue Doppler 
imaging in relatively small groups of SSc patients, have also suggested an impairment 
in myocardial systolic deformation (strain), despite preserved LVEF and dimensions 
(4;23). However, strain analysis by tissue Doppler imaging is significantly limited by angle 
dependency (the measure changes with the insonation angle) and does not allow for the 
evaluation of all LV segments and of different directions of myocardial deformation. The 
advent of 2D speckle tracking analysis overcomes these limitations and allows angle-
independent, direct evaluation of LV global strain in all three orthogonal directions, 
providing more accurate assessment of LV function (8). 
The current study applied this novel analysis in a large cohort of SSc patients and found 
that both LV global longitudinal and circumferential strains were modestly but significantly 
impaired in SSc patients as compared to controls. The relatively small difference of strain 
values noted between the 2 groups could be explained by the fact that SSc patients in the 
present cohort were asymptomatic and had a relatively preserved functional capacity, 
suggestive of mild and subclinical cardiovascular involvement. Furthermore, dSSc patients 
showed worse values of global longitudinal and circumferential strains as compared to lSSc 
patients, confirming a more common and severe cardiac involvement in the diffuse form 
of the disease (5;24). Therefore, the use of more sensitive echocardiographic parameters 
may enable the detection of subtle LV systolic dysfunction before clinical manifestation, not 
identified by conventional approaches. Of note, both the present result and the studies from 
Mele and Kepez et al. (5;6) failed to show a significant difference in myocardial function by 
using tissue Doppler imaging derived S` velocity between SSc patients and controls. These 
findings therefore suggest that 2D speckle tracking derived strain analysis, which allows 
angle-independent and global LV functional assessment, is superior to tissue Doppler 
imaging derived S` velocity to detect subtle myocardial dysfunction in SSc patients. 
Although the mechanism underlying LV systolic dysfunction is unknown, previous studies 
have demonstrated the presence of significant myocardial fibrosis in SSc patients, using 
delayed gadolinium enhanced magnetic resonance imaging (25;26). These structural 
alterations, mainly caused by repeated focal ischemia due to abnormal vasoreactivity, may be 
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responsible for myocardial dysfunction. Interestingly in the current study, multi-directional 
strain analysis demonstrated significant impairment of longitudinal and circumferential 
strains (shortening), but not of radial strain (thickening). This finding may suggest that 
myocardial involvement of the subendocardial layer (responsible for longitudinal and 
circumferential shortening) occurs earlier as compared to the subepicardial layer (responsible 
for radial deformation), since the subendocardium is more susceptible to ischemia and 
fibrosis phenomena. Nevertheless, the exact mechanism of myocardial dysfunction requires 
further studies. 
Patients with SSc were shown to have reduced cardiopulmonary exercise capacity measured 
by VO2% predicted, which could be caused by multiple factors (27-30). Previous studies 
have suggested that lung pathology is one of the main determinants of impaired functional 
capacity in these patients (28;31). Similarly, the present study also showed the important 
role of lung function assessed by DLCO% predicted, which was independently associated 
with VO2% predicted (31). In addition, a recent study by Walkey and colleagues has 
also suggested that exercise induced LV diastolic dysfunction, undetected by resting 
echocardiography, was a cause of impaired exercise capacity (29). However, the potential 
role of LV systolic dysfunction as an important contributing factor to functional capacity, has 
not been demonstrated before. Importantly, the present study demonstrated that LV global 
longitudinal and circumferential strains were significantly related with VO2% predicted, 
independently of age, SSc subtype and lung function. This observation thus provided 
direct evidence that LV systolic dysfunction significantly contributes to impaired functional 
capacity in patients with SSc. Therefore, novel 2D speckle tracking strain analysis may be 
used in conjunction with lung function testing in order to provide a global assessment and 
monitoring of the cardiopulmonary status in SSc patients. 
Ventricular arrhythmias commonly occur in patients with SSc (32) and, are responsible for 
up to 6% of the deaths, as demonstrated by a recent study (2). In particular, the presence 
of non-sustained ventricular tachycardias has been reported in 6–10% of patients with SSc 
and showed to be significantly associated with total mortality and sudden death (31;32). In 
the current study, 24-hour ECG Holter monitoring was systematically performed in a large 
group of SSc patients and identified non-sustained ventricular tachycardias in 9% of the 
cases. Importantly at the multivariate analysis, LV systolic dysfunction, assessed by LV global 
longitudinal and circumferential strains, was the only independent predictor of ventricular 
arrhythmias (ventricular ectopics and non-sustained ventricular tachycardia). These results 
suggest that subtle LV systolic dysfunction is per se an important factor associated with 
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ventricular arrhythmias and may also reflect the extent of myocardial fibrosis, which is a 
well-known arrhythmogenic substrate (25). These novel echocardiographic parameters 
therefore represent a valuable tool to improve risk stratification of SSc patients. The current 
study underscores the need for implementing speckle tracking strain analysis in larger 
systemic sclerosis cohort studies, investigating risk stratification and potential protective 
effects of anti-arrhythmic strategies.
The current study was a cross-sectional analysis and therefore a causal relationship between 
impaired 2D speckle tracking derived strain and impaired functional capacity and ventricular 
arrhythmias in SSc patients could not be established. Moreover, the current population 
included SSc patients with preserved functional capacity and low prevalence of pulmonary 
hypertension and the results of the present study can not be extrapolated to SSc patients with 
severe cardiopulmonary involvement. Lastly, microvascular and macrovascular ischemia 
were not fully documented, since all patients had no clinical evidence of myocardial ischemia 
(neither during CPET) and invasive evaluations and/or vasoreactivity tests were therefore 
not performed. Future studies are required to evaluate the impact of both microvascular 
or macrovascular ischemia on 2D speckle tracking derived multi-directional strain in SSc 
patients.
In conclusion, patients with SSc are associated with LV systolic dysfunction measured by 
2D speckle tracking strain analysis. Importantly, LV global longitudinal and circumferential 
strains independently predicted impaired functional capacity measured by CPET and 
ventricular arrhythmias detected by 24-hour ECG Holter monitoring. The use of this 
novel imaging technique may therefore improve risk stratification and monitoring of the 
cardiovascular involvement in patients with SSc.
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Objectives: Right ventricular (RV) dysfunction is of great prognostic value in patients 
with systemic sclerosis (SSc). The aim of the present study was to assess in these patients 
the relationship between pulmonary fibrosis and elevated pulmonary pressure (PHT) with 
RV function.  
Methods: A total of 102 SSc patients who underwent thoracic computed tomography and 
transthoracic echocardiography, were included. Speckle tracking-derived RV free wall strain 
was used to assess RV function. 
Results: A total of 51 (50%) SSc patients did not have pulmonary fibrosis or PHT, 32 (31%) 
patients had pulmonary fibrosis but no PHT and the remaining 19 (19%) had both pulmonary 
fibrosis and PHT. Patients with both pulmonary fibrosis and PHT had the most impaired 
RV free wall strain (-16.8±3.1%) compared with patients with pulmonary fibrosis and no 
PHT (-21.5±3.6%) and patients with no pulmonary fibrosis and no PHT (-24.0±4.4%). All 
3 SSc groups showed impaired RV free wall strain compared with controls (-28.0±4.2%). 
Importantly, multivariate regression analysis demonstrated that pulmonary fibrosis and 
left ventricular ejection fraction were independently associated with impaired RV free wall 
strain in SSc patients.  
Conclusion: SSc patients show impaired RV function compared with controls. Both 
pulmonary fibrosis and PHT are independently associated with RV dysfunction. 
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Right ventricular (RV) dysfunction is not uncommon in patients with systemic sclerosis (SSc) 
and cardiovascular involvement is one of the leading causes of mortality in these patients 
(1-3). Potential mechanisms leading to RV dysfunction in SSc include a primary involve-
ment of the RV myocardium (fibrosis) or RV pressure overload secondary to interstitial lung 
disease and elevated pulmonary pressure (PHT) (4;5). However, limited studies have been 
performed so far to elucidate the role of these factors in the development of RV dysfunction. 
Echocardiography is systematically performed in patients with SSc in order to evaluate 
and monitor cardiac function and pulmonary pressures. However, assessment of the RV 
performance by echocardiography is particularly challenging due to the complex geometry 
of RV cavity, to the significant influence of the loading conditions and to the less definite 
endocardial border. Therefore, conventional echocardiographic measures of RV dimen-
sion and function rely often on inadequate geometric assumptions and are hampered by 
a low reproducibility (6). Recent advances in echocardiography using two-dimensional 
(2D) speckle tracking analysis have allowed direct assessment of the intrinsic myocardial 
deformation (strain), independent of specific geometrical assumptions or loading condi-
tions. Echocardiographic speckle tracking-derived strain has been therefore proposed as a 
sensitive and accurate measure of regional and global RV systolic function (7). 
The aim of the present study was to assess RV systolic function using 2D speckle tracking-
derived strain echocardiography in a large cohort of SSc patients, and to identify the potential 
role of pulmonary fibrosis and PHT in the development of RV dysfunction in these patients.
Patients and methods
Patients and protocol
The current study included 102 consecutive patients with SSc referred to the department of 
Rheumatology, Leiden University Medical Center. The patients were recruited from a study 
evaluating the outcomes of diagnostic multidisciplinary health-care program, as previously 
described (8;9). 
All patients underwent an extensive screening, including detailed physical examination, 
a Modified Rodnan Skin Score assessment (10), laboratory testing (including erythrocyte 
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sedimentation rate, anti-nuclear, anti-topoisomerase I and anti-centromere antibodies 
assessments), and pulmonary function testing (PFT). Patients were classified as limited 
cutaneous systemic sclerosis (lSSc) or diffuse cutaneous systemic sclerosis (dSSc), 
according to the classification system described by LeRoy et al. (11). Furthermore, all 
SSc patients included in this analysis also underwent a thoracic computed tomography 
(CT) for detailed evaluation of the presence and extent of pulmonary fibrosis. In addition, 
transthoracic echocardiography was performed to evaluate conventional parameters of 
cardiac function and to assess subclinical RV systolic dysfunction using 2D speckle tracking 
strain echocardiography. The physicians who analyzed these studies were blinded to the 
clinical status of the patients. 
A total of 36 normal individuals (1:3 ratio with SSc patients) matched for age and gender 
(51±12 vs.54±14 years, p=0.22, and female gender 69% vs. 76%, p=0.51) were included as 
a control group for comparison. These subjects were referred for an echocardiographic 
assessment for atypical chest pain, palpitations, or syncope without murmur and all of them 
showed normal cardiac structure and function and normal pulmonary pressures.
The study protocol was approved by the Ethics Committee of the Leiden University Medical 
Center all participants provided written informed consent.
Pulmonary function testing
PFT was performed in all SSc patients including spirometry and carbon monoxide (DLCO) 
transfer studies according to the American Thoracic Society/European Respiratory Society 
recommendations and expressed as percentage predicted (12;13). 
Thoracic computed tomography
Non-contrast high-resolution CT imaging of the chest was performed using a Toshiba 
Aquilion 64 CT scanner (Toshiba Medical System, Otawara, Japan). Scan parameters were: 
slice collimation 64 x 0.5 mm, tube voltage 120 kV, tube current 110–220 mA (dependent on 
weight), rotation time 0.4 sec, helical pitch 53. Data was reconstructed as 0.5 mm/0.4 mm 
slices. Two observers (LK and AS), scored the CT investigations in consensus. Observers 
were blinded for clinical information. The images were scored as previously described 
(14). Briefly, three chest levels were identified at the level of the aortic arch, the carina and 
1 cm above the diaphragm. In particular, a total of 9 areas were assessed including (i) right 
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upper lobe at aortic level, (ii) left upper lobe at aortic level, (iii) right upper lobe at carina 
level (vi) right lower lobe at carina level, (v) left upper lobe at carina level, (vi) left lower 
lobe at carina level, (vii) right middle lobe at diaphragmatic level (viii) right lower lobe at 
diaphragmatic level, (ix) left lower lobe at diaphragmatic level. Each lobe of the lung was 
scored on a scale of 0–5 (reticulation and/or honeycombing), depending on the percentage 
of each lobe involved (0 = no fibrosis, 1 = interlobular septal thickening, 2 = honeycombing 
with or without septal thickening involving <25% of the lobe, 3 = honeycombing with or 
without septal thickening involving 25–49% of the lobe, 4 = honeycombing with or without 
septal thickening involving 50–75% of the lobe, 5 = honeycombing with or without septal 
thickening involving >75% of the lobe. The scores for each lobe were added (maximum 
score of 45) for data analysis of pulmonary fibrosis score. Patients with a total thoracic CT 
fibrosis score of ≥7 were considered to have clinical relevant pulmonary fibrosis, since a 
score of ≥7 was only observed when there was honeycombing in at least one lobe besides 
septal thickening. 
Conventional 2-dimensional echocardiography
All SSc patients and controls were imaged using a commercially available system (Vingmed 
Vivid 7, General Electric Vingmed Ultrasound, Milwaukee, USA). Images were obtained 
using a 3.5-MHz transducer and digitally stored in cine-loop format. Subsequent offline 
analysis was performed using EchoPAC version 111.0.0 (General Electric – Vingmed, 
Horten, Norway). LV volumes and ejection fraction (EF) were measured according to 
biplane Simpson’s method as currently recommended (15). RV end-diastolic area (RVEDA) 
was also measured as recommended from the apical 4-chamber view, and tricuspid annular 
plane systolic excursion (TAPSE) was measured at the level of the RV free wall to evaluate 
RV systolic function. In particular, the M-mode cursor was placed through the tricuspid 
annulus at the free wall and the total displacement of the RV base from end-diastole to 
end-systole was measured (16). 
Evaluation of LV diastolic function was based on the pulsed-wave Doppler of mitral valve 
inflow as recommended by the American Society of Echocardiography (17), measuring 
peak early (E) and late (A) diastolic velocities, their ratio (E/A) and the E wave deceleration. 
Using tissue Doppler imaging, the early diastolic velocity (E’ ) measured at the level of the 
LV basal lateral segment. In addition, E/E’  ratio was calculated as an estimation of LV filling 
pressure (18). LV diastolic dysfunction was therefore categorized as previously described: 
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normal, mild, moderate and severe (17). Pulmonary arterial systolic pressure (PASP) was 
estimated by RV systolic pressure, which was calculated from the tricuspid regurgitation 
peak gradient using Bernoulli equation, and adding right atrial pressure estimated by the 
dimension and the degree of inferior vena cava respiratory collapse (19). Patients were 
considered to have PHT if PASP was >35 mmHg (6;11).
Therefore, based on the evaluation of the CT scan and the conventional echocardiogram, 
SSc patients were categorized into the following subgroups: (1) no pulmonary fibrosis and 
no PHT, (2) pulmonary fibrosis and no PHT and (3) pulmonary fibrosis and PHT. 
2-dimensional speckle tracking right ventricular strain analysis
Two-dimensional speckle tracking analysis is a novel echocardiographic technique which 
evaluates myocardial deformation by tracking natural myocardial acoustic markers (speckles) 
in a frame-to-frame basis within the cardiac cycle. RV longitudinal strain, evaluating the 
shortening (= negative % values) and lengthening (back to initial length = zero, or stretching 
= positive % values) of the RV myocardial free wall, was assessed by 2D speckle tracking 
echocardiography from the apical 4-chamber view. The endocardial border of the RV was 
manually traced with the region of interest width adjusted to include the entire myocardium. 
The RV free wall was divided into 3 levels (basal, mid and apical) and subsequently 3 
segmental strain curves were obtained (Figure 4.1). RV free wall longitudinal strain was 
calculated as the average of peak systolic strain values of the 3 segments of the free wall, 
representing an accurate measure of global RV systolic function. Frame rate ranged from 
50 to 100 frames/s.
For the measure of RV free wall longitudinal strain, 15 patients were randomly identified for 
assessment of intra-observer and inter-observer reproducibility. According to Bland-Altman 
analysis, intra-observer reproducibility was good, with mean differences of -0.59±3.17% 
and coefficients of variation of 5.4%. Additionally, the intraclass correlation coefficient was 
0.89 (95% CI 0.73–0.96). Inter-observer variability was also good, with mean differences 
of -0.23±2.21%, a coefficient of variation of 9.6% and an intraclass correlation coefficient 
of 0.95 (95% CI 0.88–0.98).
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Continuous variables are presented as mean ± standard deviation. Categorical data are 
presented as frequencies and percentages. Continuous variables were tested for normal 
distribution with the Kolmogorov-Smirnov test. Statistical comparisons were performed 
by using Student’s T test for continuous variables, and chi-square test for binary variables. 
One-way analysis of variance (ANOVA) with post-hoc test by Bonferroni was used to 
examine the differences among groups. Correlations between clinical parameters, pulmonary 
function, thoracic CT pulmonary fibrosis score and echocardiography parameters with RV 
free wall strain were expressed in terms of Pearson’s correlation coefficient. Univariate linear 
regression analysis was used to identify potential determinants of RV free wall strain. The 
final multivariate model to identify determinants of RV free wall strain was obtained using 
the enter method by including parameters with a p-value <0.10 in univariate analysis and 
excluding parameters with significant collinearity. All statistical analysis were performed 
using the statistical package SPSS for windows (Version 17.0, SPSS, Chicago, USA). A p-value 
<0.05 was considered to be statistically significant.   
Figure 4.1 Right ventricular (RV) free wall strain assessment by 2-dimensional speckle-tracking 
echocardiography calculated from the apical 4-chamber view (left panel). 
Each color denotes the strain curve of the 3 RV free wall segments and the white dotted line represents the 
average RV free wall strain. In this example RV free wall strain is -25.0% as indicated by the arrow.




Clinical characteristics of the patients
The average CT pulmonary fibrosis score was 8.1±7.4. A total of 51 (50%) patients did 
not have pulmonary fibrosis and did not have PHT, 32 (31%) patients had pulmonary 
fibrosis but no PHT and the remaining 19 (19%) had pulmonary fibrosis and PHT. Clinical 
characteristics of the 3 groups are shown in Table 4.1. Age, gender, dSSc, Modified Rodnan 
Skin Score and blood pressure were similar between the 3 groups of SSc patients. Patients 
with pulmonary fibrosis and PHT had a longer duration of the disease (since onset of skin 
manifestation) compared with the remaining two groups of patients. Auto-antibodies 
(anti-nuclear, anti-topoisomerase and anti-centromere), current immunosuppressive and 
cardiovascular medications were also similar between the different groups. Moreover, SSc 
patients with pulmonary fibrosis and PHT had the lowest forced vital capacity (FVC)% and 
DLCO% compared with the remaining two groups of patients. However, the FVC% and 
DLCO% did not differ significantly between SSc patients with pulmonary fibrosis and no 
PHT and SSc patients with no pulmonary fibrosis and no PHT. 
Echocardiographic characteristics of the patients
Conventional echocardiographic parameters of LV systolic and diastolic function of SSc 
patients (divided in the 3 subgroups) and controls are shown in Table 4.2. No significant 
differences were noted in LV end-diastolic volume (92±24 ml vs. 95±16 ml, p=0.41), LV 
end-systolic volume (34±12 ml vs. 36±9 ml, p=0.44), and LVEF (62±7% vs. 62±7%, P=0.92) 
between overall SSc patients and controls. However, estimated PASP (30±11 mmHg vs. 20±6 
mmHg, p<0.01) was significantly higher in SSc patients as compared to controls, while 
E/E’  ratio (12.2±3.9 vs. 8.5±2.1, p<0.01) and LV diastolic dysfunction grade (60% vs. 14%, 
p<0.01) were significantly impaired in these patients. 
When comparing the 3 different groups of SSc patients (Table 4.2), all groups showed 
similar values of conventional echocardiographic parameters including LV and RV systolic 
function. According to the definition, SSc patients with pulmonary fibrosis and PHT showed 
significantly higher PASP as compared to the other 2 groups.
However, when using speckle tracking-derived strain for the analysis of RV function, 
significant differences among the groups were observed. In particular, RV free wall strain 
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was significantly impaired (less negative values) in SSc patients compared with controls 
(-21.9±4.7% vs. -28.0±4.2%, p<0.01). Furthermore among the 3 groups of SSc patients, 
patients with pulmonary fibrosis and PHT had the most impaired RV free wall strain 
(-16.8±3.1%) compared with patients with pulmonary fibrosis and no PHT (-21.5±3.6%) and 
patients with no pulmonary fibrosis and no PHT (-24.0±4.4%) (Figure 4.2). Moreover, SSc 
Table 4.1 Clinical characteristics of the 102 patients with systemic sclerosis (SSc) divided in patients with 
(1) no pulmonary fibrosis and no pulmonary hypertension (PHT), (2) pulmonary fibrosis and no PHT (3) 










Age (yrs) 51±13 58±12 58±15 <0.01
Female gender, n (%) 34 (77) 19 (70) 11 (73) 0.81
Diffuse type of SSc 24 (47) 16 (50) 12 (63) 0.48
Time since diagnosis, yrs 5.6±8.3 4.9±4.6 9.9±7.6 0.046
Time since onset of Raynaud’s, yrs 10.8±12.2 10.0±8.7 13.6±10.1 0.50
Time since onset of skin manifestation, yrs 6.2±8.2 5.6±4.7 11.8±8.4†‡ <0.01
Modified Rodnan Skin Score 5.0±5.5 5.2±5.8 8.1±6.8 0.33
Systolic blood pressure, mmHg 120±22 113±13 125±17 0.37
Diastolic blood pressure, mmHg 73±9 72±12 73±11 0.95
Systemic hypertension 5 (12) 3 (12) 0 (0) 0.52
Immune markers
Anti-nuclear, n (%) 40 (91) 24 (89) 12 (80) 0.52
Anti-topoisomerase, n (%) 12 (27) 10 (37) 6 (43) 0.48
Anti-centromere, n (%) 3 (7) 2 (7) 7 (8) 0.45
Chronic kidney disease, n (%) 2 (5) 5 (20) 1 (10) 0.13
Pulmonary function test
FVC% predicted 96.5±16.1 91.5±15.6 65.1±10.8†‡ <0.01
DLCO% predicted 69.0±14.5 61.0±14.7 45.1±10.9†‡ <0.01
CT pulmonary fibrosis score 2.4±2.6 12.3±3.9 16.6±7.9†‡ <0.01
Current immunosuppressive medication (%)
Corticosteroids, n (%) 2 (4) 11 (34) 7 (37) <0.01
Methotrexate, n (%) 4 (8) 3 (9) 1 (5) 0.87
Azathioprine, n (%) 2 (4) 3 (9) 3 (16) 0.24
Current cardiovascular medications (%)
Calcium antagonists, n (%) 21 (41) 12 (38) 10 (53) 0.56
ACE inhibitors, n (%) 4 (8) 3 (9) 1 (5) 0.87
ACE, angiotensin converting-enzyme; dSSc, diffuse systemic sclerosis; CT, computed tomography; DLCO, 
diffusion lung capacity for carbon monoxide; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; 
PHT, pulmonary arterial hypertension; Chronic kidney disease was defined as an estimated glomerular filtration 
clearance rate <60 ml/min/1,73m2 for more than 3 months.
† p<0.05 vs. patients no pulmonary fibrosis and no PHT; ‡ p<0.05 vs. patients with pulmonary fibrosis and no PHT.
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Table 4.2 Conventional echocardiographic characteristics of left and right ventricular performance in 













LV end diastolic volume (ml) 95±16 89±21 98±29 90±24 0.22
LV end systolic volume (ml) 36±9 33±10 36±14 35±12 0.65
LV ejection fraction (%) 62±7 62±7 64±7 61±7 0.30
LV diastolic function, n (%)
Normal 31 (86) 17 (33) 15 (47) 9 (47) 0.17
Mild 4 (11) 12 (26) 5 (16) 8 (42)
Moderate 1 (3) 13 (29) 8 (42) 1 (5)
Severe 0 (0) 6 (12) 4 (11) 1 (5)
E/E’  ratio 8.5±2.1 11.9±4.2 12.2±3.1 13.3±4.4 0.60
RVDA (ml) 18.3±2.4 17.3±3.5 17.9±3.8 19.8±4.2† 0.053
TAPSE (cm) 2.3±0.2 2.1±0.2 2.1±0.3 2.0±0.2 0.08
PASP (mmHg) 20±6 26±5 28±6 47±10†‡ <0.01
LV, left ventricular; PASP, pulmonary arterial systolic pressure; PHT, pulmonary arterial hypertension; RVDA, 
right ventricular end-diastolic area; TAPSE, tricuspid annular plane systolic excursion.
† p<0.05 vs. patients no fibrosis and no PHT; ‡ p<0.05 vs. patients with fibrosis and no PHT.
Figure 4.2 Right ventricular free wall strain in controls and patients with SSc (3 subgroups including [1] 
no pulmonary fibrosis and no PHT, [2] pulmonary fibrosis and no PHT and [3] pulmonary fibrosis and PHT). 
* p<0.05 vs. control; † p<0.05 vs. patients no pulmonary fibrosis and no PHT; ‡ p<0.05 vs. patients with pulmonary 
fibrosis and no PHT.
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patients with pulmonary fibrosis and no PHT showed significantly more impaired RV free 
wall strain as compared to patients with no pulmonary fibrosis and no PHT. Importantly, 
RV free wall strain was significantly more impaired in SSc patients with no pulmonary 
fibrosis and no PHT as compared to controls. 
Correlates of right ventricular free wall strain
Univariate linear regression analysis revealed that age, FVC%, DLCO%, CT pulmonary 
fibrosis score, CT evidence of pulmonary fibrosis, LVEF and PASP were significantly 
associated with impaired RV free wall strain. To avoid multicollinearity, only DLCO% was 
entered into the model. At multivariate analysis, CT evidence of pulmonary fibrosis, LVEF 
and PASP were independently associated with impaired RV free wall strain (Table 4.3).
Table 4.3 Univariate and multivariate linear regression models for RV free wall strain in patients with SSc
Univariate Multivariate
β (CI) p-value β (CI) p-value
Age (yrs) 0.09 (0.03–0.16) <0.01 0.02 (-0.04–0.09) 0.53
Female gender, n (%) 1.44 (-0.72–3.60) 0.19
Diffuse type of SSc 0.90 (-0.97–2.76) 0.34
Time since diagnosis 0.12 (-0.01–0.24) 0.07 0.03 (-0.23–0.29) 0.82
Time since onset of Raynaud’s 0.02 (-0.07–0.11) 0.61
Time since onset of skin manifestation 0.12 (-0.01–0.24) 0.06 0.01 (-0.25–0.25) 0.98
Modified Rodnan Skin Score 0.06 (-0.07–0.19) 0.36
Systolic blood pressure 0.03 (-0.02–0.08) 0.18
Diastolic blood pressure 0.05 (-0.05–0.14) 0.35
Pulmonary function test:
FVC% predicted -0.08 (-0.13–-0.03) <0.01
DLCO% predicted -0.11 (-0.16–-0.06) <0.01 -0.03 (-0.08–0.03) 0.35
CT pulmonary fibrosis score 0.28 (0.17–0.40) <0.01
Pulmonary fibrosis (CT pulmonary 
fibrosis score >7)
3.93 (2.22–5.64) <0.01 2.18 (0.25–4.11) 0.03
LV ejection fraction -0.15 (-0.29–-0.02) 0.02 -0.12 (-0.24–-0.01) 0.04
E/E’  ratio 0.15 (-0.14–0.43) 0.30
PASP 0.23 (0.16–0.31) <0.01 -0.03 (-0.08–-0.03) 0.03
Abbreviations as in Tables 4.1 and 4.2.




The main findings of the present study can be summarized as follows: 1) despite no significant 
differences in conventional echocardiographic parameters, RV free wall strain assessed by 
2D speckle tracking echocardiography was significantly impaired (less negative) in patients 
with SSc as compared to controls; 2) in particular, patients with pulmonary fibrosis and 
PHT showed the most impaired RV free wall strain, followed by patients with pulmonary 
fibrosis and no PHT. Of interest, patients without pulmonary fibrosis and no PHT had the 
most preserved RV free wall strain, although remaining significantly impaired as compared 
to controls; 3) CT evidence of pulmonary fibrosis, PASP and LVEF were independently 
associated with impaired RV free wall strain.
Impaired right ventricular function in SSc patients
The exact prevalence of RV dysfunction in SSc patients is currently unknown (20). 
Echocardiography is the most widely available and applied method to evaluate RV function 
in these patients. Since the contraction of RV occurs mainly along the longitudinal axis (21), 
the assessment of systolic displacement of the tricuspid annulus towards the apex along the 
longitudinal plane, the so-called TAPSE, is one of the most frequently used echocardiographic 
methods to estimate RV systolic function. However, initial small studies have applied 
TAPSE in SSc patients with contradictive results: some studies showed impaired TAPSE 
in SSC patients as compared to controls (22;23) while other studies showed similar values 
(24). In the present study, TAPSE was not significantly different between SSc patients and 
controls, although it showed a trend of being more impaired in a most advanced stage of 
the disease (in patients with pulmonary fibrosis and PHT). A possible explanation of these 
results might be that TAPSE reflects the contraction of a single RV segment (basal part of 
RV free wall next to tricuspid annulus) and may not accurately represent global RV systolic 
function (25). Furthermore, this measure is probably not sensitive enough to identify subtle 
RV myocardial dysfunction and is therefore significantly impaired only at a late stage of the 
disease. A diagnostic technique that could overcome these limitations and allow an early 
and accurate diagnosis RV dysfunction in SSc patients would therefore be of great clinical 
importance for patient management. 
2D echocardiographic speckle tracking strain analysis has been proposed as a sensitive tool to 
detect subtle LV dysfunction in patients with SSc (26). However, the value of this technique 
for the assessment of RV function in SSc patients is largely unknown. The present study, 
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using this novel echocardiographic technique in a large cohort of patients, demonstrated 
significantly more impaired RV function in patients with SSc (with apparently normal RV 
dimension and TAPSE) as compared with matched controls. In particular, patients with 
pulmonary fibrosis and PHT showed the most impaired RV free wall strain as compared 
with patients with pulmonary fibrosis and no PHT and patients without either condition. 
Of similar importance, SSc patients without pulmonary fibrosis or PHT still showed a 
significantly impaired RV free wall strain as compared with controls, suggesting the ability of 
this technique to diagnose subclinical direct myocardial involvement of the RV by SSc, with 
important implications in the clinical decision-making regarding the follow-up/monitor of 
cardiac function and potential early treatment. Similar results were also observed in initial 
studies which showed impaired RV function as detected by speckle tracking derived strain 
in SSc patients with no PHT (27-29).
Independent association of PASP, pulmonary fibrosis and LVEF with 
impaired RV function
Initial studies have suggested a close relationship between PHT and the development of 
RV dysfunction in SSc patients. In a study involving 98 patients with connective tissue 
disease (91 patients with SSc), RV function measured by Tei-index significantly correlated 
with pulmonary pressure derived by right heart catheterization (30). Pulmonary pressures 
were also correlated with tissue-Doppler imaging-derived RV strain rate among 23 
patients with SSc (31). These findings are further confirmed by the present study, where 
PASP independently contributed to the presence of impaired RV function, suggesting the 
detrimental effect of elevated PASP on RV performance by pressure-overload, either due 
to interstitial lung disease or to pulmonary arterial hypertension. 
Similarly, various types of pulmonary disease are associated with RV dysfunction. In a study 
involving 434 patients with severe pulmonary disease, RV dysfunction was present in 66% 
of patients and the prevalence was similar between the different groups (alpha1-antitrypsin 
deficiency emphysema, chronic obstructive airway disease, cystic fibrosis and idiopathic 
pulmonary fibrosis) (32). Another study also demonstrated that in patients with interstitial 
lung disease (n=22), RV dysfunction was common and significantly correlated with exercise 
capacity (33). The association between pulmonary fibrosis and RV dysfunction in patients 
with SSc has not been explored. The present study demonstrated in a large cohort that 
patients with pulmonary fibrosis, detected by high-resolution CT thorax, had impaired RV 
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free wall strain, even without associated PHT. In addition, presence of pulmonary fibrosis 
was independently associated with RV dysfunction after multivariate adjustment. A potential 
explanation of this finding is that pulmonary fibrosis may be associated with mild/latent 
or dynamic PHT, which could not be detected by a single echocardiography measurement 
(34). In addition, patients with pulmonary fibrosis have been shown to be more likely to 
have systemic involvement, and are therefore probably at higher risk for a significant direct 
myocardial involvement contributing to RV dysfunction (35). These hypotheses, however, 
require further studies. 
In the current study, LVEF was also independently associated with RV free wall strain in 
patients with SSc. Only limited data are available on the relationship between LV and RV 
function in SSc patients. In a study of 42 SSc patients, 16 of them showed impaired RV ejection 
fraction and 8 of them had concomitant LV diastolic dysfunction (2). The concomitant 
presence of RV and LV dysfunction can be explained by a primary myocardial involvement, 
which is common in patients with SSc and can occur simultaneously in both RV and LV, 
leading to biventricular dysfunction (36). In addition, RV and LV performance are closely 
related as they share a common ventricular septum and RV epicardial fibers are contiguous 
with LV epicardial fibers. This inter-ventricular interaction can play a significant role in SSc 
patients, particularly since RV dilatation and elevated PASP may influence LV filling and 
subsequently LV diastolic and systolic function (37).
Limitations
The cross-sectional design of the study precluded the establishment of causal relationship 
between 2D speckle tracking derived RV free wall strain with pulmonary fibrosis and PASP 
in patients with SSc. In addition, PASP was estimated with echocardiography and right heart 
catheterization was not systematically available, since it was performed only at the discretion 
of the treating physician after joint discussion within the PHT working group. Therefore, 
PASP measured in the present study was considered to be a general measure of RV overload. 
Also in this analysis, tissue Doppler imaging derived measures of RV function were not 
performed. However, 2D speckle tracking analysis should be considered more accurate for 
RV function assessment since it overcomes the main limitation of tissue Doppler imaging 
which is the dependency of the insonation angle, often significant in the visualization of 
the RV free/wall (29). Finally, the findings of the present study should be confirmed in 
larger prospective studies eventually exploring also the prognostic value of these measures.
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Patients with SSc showed impaired RV function as assessed by 2D speckle tracking derived 
strain as compared to controls. CT evidence of pulmonary fibrosis, PASP and LVEF were 
independently associated with impaired RV free wall strain.
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Background: Dyspnea may be a presenting symptom in progressive systemic sclerosis (SSc). 
Respiratory drive (mouth occlusion pressure, MOP, at rest and during CO2 rebreathing, 7% 
CO2, 93% O2) is a major determinant of dyspnea and may relate to the magnitude of dyspnea. 
Methods: In a prospective design, MOP at 0.1 sec (P0.1) was measured in 73 SSc patients 
while breathing room air and during CO2 rebreathing. An abnormal V’E/P0.1 is defined 
as <8 L/min/cmH2O. Dyspnea scores were assessed by a shortness of breath questionnaire 
(UCSD dyspnea scale). 
Results: Mean P0.1 in patients with normal V’E/P0.1 (n=45) was 1.1±0.04 and 1.6±0.08 
cmH2O in patients with abnormal V’E/P0.1 (n=28), p<0.001. ∆P0.1/∆ PetCO2 differed 
significantly between these groups (0.45 versus 0.75 cmH2O/mmHg, p<0.001), but no 
significant difference was present in ∆V’E/∆PetCO2. V’E/P0.1 showed the highest significant 
correlation with the UCSD dyspnea score (r=-0.76, p<0.001). UCSD cut-off value for 
abnormal V’E/P0.1 was 8.5 (sensitivity 93%, specificity 96%, area under the curve 0.98).  
Conclusions: In SSc patients an abnormal V’E/P0.1 better relates to the severity of dyspnea 
than traditional lung function parameters and can easily be assessed at first outpatient 
consultation. 
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Systemic sclerosis (SSc) is a rare, heterogeneous condition of unknown etiology character-
ized by microvascular injury and deposition of excess collagen in skin and internal organs 
(1). Principle subsets of SSc include limited cutaneous SSc (lcSSc) and diffuse cutaneous 
SSc (dcSSc) (2). Importantly, progressive systemic sclerosis may involve interstitial lung 
disease (ILD) resulting into a restrictive lung function pattern abnormality (1). In addition, 
pulmonary arterial hypertension (PAH) may arise in the course of the disease (1). Validated 
measures to monitor progression of SSc are necessary for clinical trials and routine care of 
patients with SSc. Dyspnea as a presenting symptom occurs in 20% of all newly diagnosed 
SSc patients and 70% of patients with SSc complicated by ILD or PAH patients complain of 
dyspnea (1). Importantly, early recognition of disease progression related to organ damage 
and initation of treatment may improve health-related outcomes. Lung volumes and gas 
transfer studies are related to disease severity in SSc (1) and used for initation of treatment 
and evaluation. However, whether the magnitude of dyspnea relates to these pulmonary 
function tests is not known. 
The impedance of the respiratory system is influenced by lung and chest wall compliance 
and respiratory flow resistance (3). An increased respiratory impedance is recognized as the 
most frequent cause of dyspnea (3). Other respiratory abnormalities resulting into dyspnea 
may include hypoxia, respiratory muscle weakness or pulmonary vasculopathy (pulmonary 
embolisms, pulmonary arterial hypertension). In progressive SSc, dyspnea may arise from 
an increased impedance of the respiratory system caused by ILD. In SSc, ILD or limited 
chest wall excursions due to a thickened thoracic skin is considered to cause this increased 
impedance (4;5). Furthermore, dyspnea may result from an inappropriate ventilatory re-
sponse upon the chemoreflex drive at rest and to hypercapnia (6;7).  
To assess the ventilatory output as an index of the respiratory drive, resting ventilation 
(V’E) and tidal volumes can be evaluated (8). Ventilation, however, is an imperfect output 
parameter of the respiratory drive since it is affected by alterations in the impedance of the 
respiratory system (i.e. mechanical properties of the lung and chest wall) independently 
of changes in respiratory sensitivity to hypercapnia (3;6;9). To assess the respiratory drive, 
mouth occlusion pressures (MOP) as an index of the output can be measured (3). Important 
advantages of this technique include the reproducibility within each subject and reported 
values independent of age (10). In a study of normal subjects and patients with ILD, a V’E/
P0.1 greater than 8 l/min/cmH2O sharply separated a normal from an abnormal response 
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(10). Therefore, in patients who report dyspnea and who have concomitant ILD, a low V’E 
to a high P0.1 (i.e. low V’E/P0.1) is expected.  
In addition to V’E/P0.1 at rest, the respiratory drive to hypercapnia (P0.1 to CO2, i.e. 
∆P0.1/∆PetCO2) provides insight into the central chemoreflex drive to hypercapnia (11-
13). In patients with ILD and dyspnea, the central chemoreflex drive may result into a 
falsely low ventilatory response to hypercapnic stimulation (7). To overcome this, the 
central chemoreflex drive to hypercapnia may be assessed by mouth occlusion pressures 
(∆P0.1/∆PetCO2) (6;11;12). 
Based on the above we hypothesized that in patients with SSc the respiratory drive, as 
measured by P0.1, V’E/P0.1 and mouth occlusion pressures to CO2 rebreathing, may better 
relate to the magnitude of reported dyspnea than the severity of gas transfer or lung volume 
impairment as measured by PFTs. Furthermore, we hypothesized that the respiratory drive 
to hypercapnia is increased in SSc patients who reported dyspnea.
Methods
Patients
We prospectively screened SSc patients referred to an outpatient targeted health care 
program. All patients underwent an intensive screening procedure which included 
PFTs, serum laboratory testing, echocardiography, high-resolution chest CT scanning 
(HRCT) and a cardiopulmonary exercise test (CPET). Furthermore, all patients consulted 
a rheumatologist, cardiologist and a pulmonologist. All tests were done in one or two 
consecutive days. Patients were classified as limited systemic sclerosis (lcSSc) or diffuse 
systemic sclerosis (dcSSc) according to the LeRoy criteria (2). 
Ethics
The local Medical Ethical Committee of the Leiden University Medical Center approved the 
protocol. A written informed consent was obtained from each patient prior to enrollment. 
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Standard pulmonary function testing
PFTs were measured in all SSc patients including spirometry and gas transfer studies and 
expressed as percentage predicted (14;15). Total lung capacity (TLC) was measured by the 
multiple breath helium dilution method and diffusion capacity for carbon monoxide (DLCO) 
by the single breath carbon monoxide method (14;15). 
Measuring mouth occlusion pressures during resting ventilation and 
CO2 rebreathing 
Subjects were seated comfortably, attached to the mouthpiece with a noseclip in place. 
At randomized intervals, and without the subject’s knowledge, the inspiratory side of the 
rebreathing circuit was occluded during late expiration. The pressure generated at 0.1 s 
after the onset of inspiration was obtained in each subject during several minutes with 
a minimum of 10 measurements prior to the rebreathing test (3). Thereafter, occlusion 
pressures were measured simultaneously during CO2 rebreathing at randomized intervals 
(3;16). The slope of this curve was used as an index of the respiratory drive to hypercapnia 
(i.e. central chemoreflex drive) and reported as ∆P0.1/∆PetCO2 (3;16)
Measuring the hyperoxic ventilatory response to hypercapnia (HCVR)
We used a simple rebreathing technique according to Read’s rebreathing technique, which 
consisted of a rebreathing bag filled with a gas mixture (7% CO2 and 93% O2) (17). In the 
rebreathing bag, a total volume of approximately twice the measured vital capacity of the 
patient was used.
Under hyperoxia the ventilatory response to hypercapnia (HCVR) represents the central 
chemoreflex response only, assuming that the peripheral chemoreflex drive is suppressed 
by hyperoxia (16;17). Equilibrium of pressures between CO2 in cerebral blood and end-tidal 
PCO2 exhalation at the mouth (PetCO2) is expected not to occur before recirculation of 
cerebral blood flow (17). Respiratory volumes were recorded by a turbine volume measuring 
device (Oxycon-Pro, Jaeger). The Oxycon Pro was calibrated according to the instruction 
manual before each test (Oxycon instruction manual ver. 4.5. Erich Jaeger GmbH, Hoechberg, 
Germany) (18). Oxygen and CO2 analyzers were calibrated with room air and certified 
calibration gases at 180 kPa (16% O2, 5% CO2and 79% N2). The flow turbine (Triple V, Erich 
Jaeger GmbH, Hoechberg, Germany) was calibrated with a 3.00 liter 5530 series calibration 
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syringe (Hans Rudolph, Inc, Kansas City, USA). Both gas and volume calibration were 
repeated until the difference between consecutive calibrations was less than 1%. Therefore, 
measurements were not considered to be influenced under hyperoxia. Expired gas at the 
mouth was sampled continuously and analyzed for PetCO2 by a fast-response infrared 
analyzer. The software calculated tidal volumes, inspiratory and expiratory times, minute 
ventilation, and PetCO2 on a breath-by-breath basis. The hyperoxic ventilatory response to 
hypercapnia (HCVR) was measured during several minutes after equilibrium between the 
end-tidal CO2 and mixed venous CO2. In this phase, a linear increase in V’E with respect 
to PetCO2 was observed. The slope of this curve was used as the index of the ventilatory 
central chemosensitivity and reported as ∆V’E/∆PetCO2 (17). 
UCSD shortness of breath questionnaire 
We used a previously validated shortness of breath questionnaire which evaluates in 24-items 
self-reported shortness of breath while performing a variety of activities of daily living (19). 
It was administered by MKN prior to the MOP and rebreathing study while the subject 
sitting comfortably.  
Statistical analysis
Statistical analysis was performed with the SPSS 20.0 package (SPSS, Inc., Chicago, IL, USA). 
Continuous variables are expressed as mean value ± standard deviations. P-values <0.05 
were considered significant. Categorical data are presented as frequencies and percentages. 
Statistical comparisons were performed by using Student’s T-test for continuous variables, 
and chi square test for binary variables. Correlations between clinical parameters, pulmonary 
function tests, were expressed in terms of Pearson’s or Spearman’s correlation coefficient 
when appropriate. The receiver operating characteristic (ROC) curve was used to evaluate 
the optimal cut-off value for the UCSD dyspnea score in relation to an abnormal V’E/P0.1. 
Results
In total, 73 SSc patients were prospectively evaluated by measuring PFTs, MOP and the 
hyperoxic ventilatory response to hypercapnia (HCVR). Patients were classified by their 
V’E/P0.1 according to Scott GC and Burki NK [10], where ≥8 l/min/cmH2O was defined 
as normal. 
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Anthropometric and lung function data are presented in Table 5.1. In the group with a 
V’E/P0.1 ≥8 L/min/cmH20, lcSSc patients were significantly more present. In all patients 
with an abnormal V’E/P0.1 (<8 L/min/cmH2O), spirometric and gas transfer studies were 
significantly lower. All SSc patients were normocapnic at rest (PaCO2=5.24±0.41 kPa).








Age (yrs) 54.4 (11.8) 50.9 (14.4) 0.25
Female sex (%) 26 (93) 37 (82) 0.11
Height (cm) 164 (7.2) 171 (8.7) 0.002
Weight (kg) 67.1 (15.3) 69.8 (12.8) 0.43
BMI (cm/kg2) 24.8 (5.4) 23.9 (3.7) 0.48
lcSSc subtype (%) 10 (36) 34 (76) 0.02
PaO2 (kPa) 10.4 (0.36) 10.6 (0.29) 0.58
PaCO2 (kPa) 5.31 (0.41) 5.18 (0.43) 0.25
FVC (% pred) 92.1 (19.9) 111.1 (19.7) 0.001
DLCOc SB (% pred) 57.7 (15.8) 70.7 (15.1) 0.001
TLC-He (% pred) 81.5 (16.6) 95.4 (13.5) <0.001
FRC/TLC (%) 53 (17) 56 (7) 0.23
* P-value expressed for student T-test.
PaO2 (partial arterial oxygen pressure, kPa); PaCO2 (partial arterial carbon dioxide pressure, kPa); FVC (forced 
vital capacity, % pred); DLCOc SB (diffusion capacity for carbon monoxide single breath, % pred); TLC-He (total 
lung capacity, helium-dilution, % pred); FRC/TLC (ratio of functional residual capacity and TLC, %).
Indices of MOP differed significantly between the two groups (Table 5.2). In contrast, 
there was no difference in the hyperoxic ventilatory response to hypercapnia. In our study, 
patients with a normal V’E/P0.1 had a mean ∆P0.1/∆PetCO2 of 0.45±0.19 cmH2O /mmHg, 
which differed significantly from patients with an abnormal V’E/P0.1. The latter group had 
an increased respiratory drive to hypercapnia (mean ∆P0.1/∆PetCO2 0.75±0.42 cmH2O/
mmHg). 
All pulmonary function test parameters correlated inversely and significantly with the UCSD 
shortness of breath questionnaire (coefficient of correlation ranging from -0.39 to -0.49). 
V’E/P0.1, however, showed the highest significant correlation with the UCSD dyspnea score 
(r=-0.76, p<0.001, Figure 5.1). The cut-off value in UCSD dyspnea score for an abnormal 
V’E/P0.1 was 8.5 (sensitivity 93%, specificity 96%, area under the curve 0.98).




We report that in SSc patients with an abnormal inspiratory respiratory drive (V’E/P0.1 
<8 L/min/cmH2O) the sensation of dyspnea as measured by the UCSD dyspnea score 
differed from SSc patients with a normal respiratory drive. In addition, with a cut-off 
value of 8.5, the dyspnea score showed a high sensitivity and specificity for an abnormal 
V’E/P0.1. Furthermore, an abnormal V’E/P0.1 better relates to the magnitude of dyspnea 
than traditional lung function parameters and in these SSc patients an increased central 







UCSD SOBQ 13 (3.5) 2.2 (2.7) <0.001
P0.1 1.60 (0.57) 1.10 (0.31) <0.001
V’E 8.7 (2.3) 11.6 (3.5) <0.001
V’E/P0.1 5.68 (1.24) 10.83 (2.46) <0.001
∆V’E/∆PetCO2 2.31 (2.0) 2.49 (1.76) 0.71
(∆V’E/FVC)/∆PetCO2 0.93 (0.72) 0.57 (0.51) 0.07
∆P0.1/∆PetCO2 0.75 (0.42) 0.45 (0.19) 0.01
* P-value expressed for student T-test.
UCSD SOBQ (shortness of breath questionnaire; score range 0–120); P0.1 (mouth occlusion pressure at 0.1 
second; cmH2O); V’E (minute ventilation; L/min); V’E/P0.1 (central inspiratory neuromuscular respiratory drive; L/
min/cmH2O); ∆V’E/∆PetCO2 (hyperoxic ventilatory response to hypercapnia; L/min/mmHg); (∆V’E/FVC)/∆PetCO2 
(hyperoxic ventilatory response to hypercapnia, corrected for FVC; FVC/min/mmHg); ∆P0.1/∆PetCO2 (slope of 
occlusion pressure to hypercapnia; cmH2O/mmHg).
Figure 5.1 Correlation between the UCSD dyspnea score (19) and V’E/P0.1 in 73 prospectively screened 
SSc patients. 
Vertical line set at V’E/P0.1 = 8 L/min/cmH2O. Horizontal line set at UCSD 8.5.
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chemoreflex drive to CO2 is present. Therefore, at first outpatient consultation, SSc patients 
complaining of dyspnea can easily be classified by using mouth occlusion pressures. 
We showed that the level of dyspnea perception measured by the UCSD shortness of breath 
questionnaire (19) had a strong inverse correlation with the inspiratory neuromuscular drive 
as measured by V’E/P0.1 (Figure 5.1). A high dyspnea score and an increased respiratory 
drive to hypercapnia suggest that the work of breathing is increased due to an increased 
respiratory impedance (7;10). An increased activation of central respiratory centers results 
not only into an increase in minute ventilation but also into an increased perception of 
dyspnea (20). The basis for this awareness originates from the exchange in information 
between the motor and sensory cortex and is referred to as corollary discharge (20). Although 
the work of breathing is not the sole cause of dyspnea, increased effort as a result from an 
increased mechanical load causes a heightened sense of respiratory effort. Consequently, 
this may explain the strong correlation between the dyspnea score and the respiratory drive 
in the present study. This drive can be easily measured using mouth occlusion pressures at 
rest. As our results indicate, it better relates to dyspnea than impairment in lung volumes 
or gas transfer and may be present before significant impairment in these function tests 
arises. Therefore, measurement of the neuromuscular inspiratory drive may function in 
clinical practice in SSc patients complaining of dyspnea as a screening tool for detection 
of ILD or PAH. 
Ventilation and its components, tidal volume and breathing frequency, depend on the 
compliance of the respiratory system and airway resistance (3;9-11). Importantly, one would 
like to differentiate patients who will not breathe because of central or neuromuscular 
inadequacy from those who cannot breathe because of mechanical abnormalities of the 
chest. The ventilatory response to hypercapnia is known for its large variability and reported 
responses may vary from 2.0 to 4.7 L/min/mmHg (3;17). Although a correction by FVC 
will lead to less variability (reported values vary from 0.42 to 0.94 FVC/min/mmHg (3), 
measuring the respiratory drive in patients affected by ILD using ventilatory parameters 
remains troublesome. 
The mouth occlusion pressure generated by the inspiratory muscles at functional residual 
capacity (P0.1) has been proposed as a useful test to avoid these disadvantages (3;9-11). It 
is independent of flow resistance and respiratory compliance and less variability is observed 
in various subjects (3;10). Taken this together, we argue that ventilation and its components, 
may not represent an accurate output of the respiratory drive in our patients.
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In daily practice, measuring P0.1 is very simple to apply and joined with a rebreathing bag, 
measurement of CO2 responsiveness is possible. In normal subjects, P0.1 values of 0.75–1.5 
cmH2O have been described (3;10). In addition, normal V’E/P0.1 is defined by ≥8 L/min/
cmH2O, as evaluated by Scott and Burki (10). The responsiveness to hypercapnia by measuring 
P0.1 (∆P0.1/∆PetCO2) in normal subjects is reported to be 0.17–0.49 cmH2O /mmHg (3;16). 
This is in agreement with our results of SSc patients with a normal V’E/P0.1 (Table 5.2, 
mean ∆P0.1/∆PetCO2 0.45 cmH2O/mmHg). Thus, in these SSc patients, the respiratory 
compliance and airflow resistance did not affect occlusion pressures or the responsiveness 
to hypercapnia and is therefore considered to be normal. Furthermore, our data of mouth 
occlusion pressures during resting minute ventilation and during CO2 rebreathing in patients 
with normal V’E/P0.1 are consistent with those of others (3;7;10;16;21). However, in the 
present study no significant difference was seen in ∆V’E/∆PetCO2 between the groups as 
classified by V’E/P0.1 (Table 5.2). Since there was a significant difference present between 
these groups using mouth occlusion pressures, minute ventilation may not represent the 
neuromuscular drive adequately in SSc patients with an increased respiratory impedance. 
Although our reported values of the respiratory drive, as measured by P0.1, were approxi-
mately similar, differences from those previously reported by Walterspacher et al. are 
present (21). Potential reasons may include the differences in degree of restrictive lung 
function as measured by FVC % predicted. Our SSc patients with an abnormal V’E/P0.1 
had mildly reduced FVC % predicted and may have preserved inspiratory muscle function. 
Furthermore, our SSc patients did not avoid activities provoking dyspnea resulting into 
deconditioning and muscle wasting. Secondly, they did not use immunosuppressive agents 
affecting respiratory muscle function (prednisone). Finally, polyneuropathy, which may 
cause an impaired respiratory muscle function, was not likely in our patients. Therefore, 
respiratory drive was considered to be appropriate in our SSc population. 
In our study, patients with a low V’E/P0.1 had an increased responsiveness to hypercapnia 
which suggests an increased central respiratory drive (Table 5.2). This group was characterized 
by fewer limited SSc patients, a lower forced vital capacity, more impaired gas transfer and 
a lower lung volume (Table 5.1). Importantly, the majority of these patients had evidence 
of interstitial lung disease on their HRCT and some patients had an elevated tricuspid 
insufficiency gradient (data not shown). The disease duration did not differ between these 
groups. The difference in V’E/P0.1 between the groups are related to SSc disease severity 
and therefore influence the impedance of the respiratory system. Consequently, differences 
in V’E/P0.1 were observed. 
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Similar results are reported by Gorini and coworkers in normocapnic ILD patients without 
SSc (7). This contrasts to the concept of gradual down-regulation in central respiratory 
sensitivity for carbon dioxide in scleroderma patients (4). DiMarco and coworkers concluded 
that in patients with ILD, non-chemical, and presumably neural, mechanisms, both increase 
respiratory drive and alter the breathing pattern (22). 
Several factors may influence the central sensitivity to CO2 as measured by the ventilatory 
response to hypercapnia, such as the hormonal status, sex, age, use of sedative agents and 
caffeine (8;17). However, these factors will generally not result into an abnormal V’E/P0.1 
since the compliance of the respiratory system or airway resistance is not affected. 
Some considerations may apply to our study. First, we evaluated MOP and CO2 rebreathing 
in patients with systemic sclerosis. We used a dataset of normal values for normal resting 
minute ventilation as a function of occlusion pressures (V’E/P0.1) (10). As reported by others 
a value higher than 8 L/min/cmH2O, independent of age or sex, identifies subjects with 
normal PFTs and therefore provides a reliable index of respiratory drive (3;10). Consequently, 
we restricted our measurements in a patient group, only classified by V’E/P0.1. Our study 
contained 73 patients, which was similar to previous studies evaluating mouth occlusion 
pressures (3;10), and considered to be sufficient for group difference statistics. Despite the 
relatively mild range in low dyspnea scores (range 0–21; Figure 5.1), a significant difference 
in V’E/P0.1 and ∆P0.1/∆PetCO2 was present (Table 5.2), indicating the sensitivity of the 
mouth occlusion pressure test. Furthermore, assessing V’E/P0.1 to an additional load such 
as exercise may have increased this difference since airflow resistance will increase and 
consequently the impedance of the respiratory system. 
Secondly, we did not measure the sensation of dyspnea, as assessed at rest by the UCSD 
questionnaire, during CO2 rebreathing. To evaluate the relationship between the intensity 
of dyspnea and respiratory chemosensitivity may have strengthened our results, however 
this questionnaire was not designed to be administered during a rebreathing or exercise test. 
In summary, the results of the present study show that patients with systemic sclerosis 
display a substantial variability in the ventilatory response to hypercapnia. In contrast, mouth 
occlusion pressures, independent of respiratory compliance or airflow resistance, provide an 
accurate outcome parameter in combination with minute ventilation as an initial evaluation 
for mild dyspnea. They better relate to the magnitude of patient reported dyspnea than 
traditional lung function parameters such as FVC or DLCO % predicted. Furthermore, in our 
SSc patients with an abnormal V’E/P0.1, an increased respiratory drive to hypercapnia was 
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present. Since dyspnea is one of the most frequently reported symptoms at first consultation 
in SSc, an easy test to discriminate between normal or abnormal respiratory mechanics 
would be obligatory. Therefore, we suggest that an abnormal V’E/P0.1 in combination with 
reported dyspnea indicates further assessment of respiratory involvement in SSc patients.
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Background: Exercise intolerance (EI) in systemic sclerosis (SSc) is difficult to manage by 
the clinician. The peripheral chemoreflex drive compensates for metabolic acidosis during 
exercise and may be related to EI.  
Aim: To assess the global peripheral chemoreflex drive (GPCD) in patients with SSc at 
rest and during exercise.  
Methods: Consecutively tested SSc patients (n=49) were evaluated by pulmonary function 
tests, carbon dioxide (CO2) rebreathing studies and non-invasive cardiopulmonary exercise 
testing (CPET). Results of their CO2 rebreathing tests were compared with those of controls 
(n=32). Respiratory compensation for metabolic acidosis during CPET was defined by the 
occurrence of a sharp increase in minute ventilation (VdotE) and the ventilatory equivalent 
for CO2 (VdotE/VdotCO2) at the end of the isocapnic buffer phase. Euoxic (eVHR) and 
hyperoxic (hVHR) ventilatory responses to hypercapnia were measured and its difference 
(eVHR-hVHR) was considered to reflect the GPCD. 
Results: In 45 patients with SSc, CPET results showed respiratory compensation at the 
occurrence of metabolic acidosis. eVHR-hVHR in patients with diffuse cutaneous SSc 
(dcSSc) differed significantly from that in patients with limited cutaneous SSc (lcSSc) and 
from that in controls (0.47±0.38 (dcSSc) versus 0.90±0.77 (lcSSc) and 0.90±0.49 (controls) 
L/min/mmHg; p=0.04 and p=0.03, respectively).  
Conclusions: Respiratory compensation for metabolic acidosis occurred in all patients. 
However, the GPCD was diminished in dcSSc patients, suggesting an altered control of 
breathing. Its assessment  may help the clinician to better understand reported exercise 
intolerance and exertional dyspnea in dcSSc patients. 
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Typically, progressive systemic sclerosis (SSc) may involve interstitial lung disease (ILD) 
and pulmonary hypertension (PH) (1). In some cases of progressive SSc, however, thoracic 
wall involvement may arise and manifest as an impairment in chest wall excursions caused 
by thickened thoracic skin, referred to as “sclerodermic chest wall” (2). The impedance 
of the respiratory system is influenced by lung and chest wall compliance and respiratory 
flow resistance (2;3). In progressive SSc, dyspnea may arise from an increased impedance 
of the respiratory system caused by ILD. In SSc, ILD or limited chest wall excursions due to 
a thickened thoracic skin is considered to cause this increased impedance. Consequently, 
ventilatory impairment as a result of restriction may occur, resulting in alveolar carbon 
dioxide (CO2) retention and subsequently in hypercapnic respiratory failure (2;3). It has 
been postulated that hypercapnic respiratory failure and exercise intolerance (EI) may, in 
contrast, involve a gradual down-regulation in central and peripheral chemosensitivity, 
resulting in slightly chronic elevated arterial partial carbon dioxide pressures (PaCO2) and 
reported dyspnea during exercise (2;3). Therefore respiratory failure and EI in SSc may 
include not only increased respiratory impedance (i.e. reduced respiratory compliance and/
or increased flow resistance), but also a diminished peripheral chemoreflex drive. Moreover, 
an absent peripheral chemoreflex drive itself may induce an early onset of metabolic acidosis 
and therefore an exercise intolerance and reported exertional dyspnea (4;5). 
The peripheral chemoreflex drive plays an important role in the control of breathing (4;5). It 
not only ensures oxygen homeostasis, but also helps maintain CO2 levels at rest and during 
exercise (4-6). Activation by peripheral chemoreceptors has been implicated in ventilatory 
compensation for metabolic acidosis during exercise (4-6). This ventilatory compensation 
is reflected in a sharp increase in the ventilatory equivalent for CO2 (VdotE/VdotCO2) at 
the end of the isocapnic buffer phase and a decrease in end-tidal pCO2 (6).
The pathophysiology of SSc is complex, involving immune activation and widespread 
vascular injury (7-9). Although SSc is primarily a microvascular disorder with perivascular 
cellular infiltrates that consist of macrophages, T cells and B cells, with a predominance 
of CD4+ T cells, macrovascular involvement has been reported as well (7-9). The carotid 
bodies, the site of the peripheral chemoreflex to oxygen, CO2 and pH, contain a complex 
microvascular anatomy in a macrovascular environment. SSc-related inflammatory and 
fibrotic responses may cause a diminished peripheral chemoreflex, which may result into an 
increased susceptibility to EI and consequently reported dyspnea during exercise (4-6;10). We 
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therefore hypothesized that the peripheral chemoreflex drive in normocapnic SSc patients is 
diminished at rest and during exercise. We obtained CO2 rebreathing studies in SSc patients 
and healthy controls, and all SSc patients performed a cardiopulmonary exercise test (CPET).
Methods
Ethics
The local Medical Ethical Committee of the Leiden University Medical Center approved the 
protocol. Written informed consent was obtained from each participant prior to enrolment 
in the study.
Patients and healthy controls
We consecutively tested 49 SSc patients referred to an outpatient health care program. 
All patients were included in the study and underwent pulmonary function tests (PFTs), 
CO2 rebreathing tests at rest and non-invasive incremental CPET on a bicycle according 
to Wasserman (6). No patients were excluded. All tests were done in one day or on two 
consecutive days between April 2010 and January 2012. Patients were classified as having 
limited cutaneous sclerosis (lcSSc) or diffuse cutaneous systemic sclerosis (dcSSc) according 
to the LeRoy criteria (11). All healthy controls performed the CO2 rebreathing tests at rest 
only; PFTs were expected to be normal.
Euoxic (eVHR) and hyperoxic (hVHR) ventilatory response to hypercap-
nia at rest
CO2 rebreathing tests were first obtained in all subjects. To assess the global peripheral 
chemoreflex drive (GPCD), we assessed the ventilatory response to hypercapnia under both 
euoxic (eVHR) and hyperoxic (hVHR) conditions as previously described (12). Briefly, under 
hyperoxia, the peripheral chemoreflex drive is considered to be suppressed for at least 30 
minutes (13;14). The central chemoreflex drive to hypercapnia can therefore best be assessed 
for several minutes during hyperoxia. When the ventilatory response to hypercapnia under 
euoxia is measured, the total chemoreflex drive consists of both central and peripheral 
chemoreflex drives (15-17). These drives are then assumed to be additive (14;17). Thus, when 
the inspiratory fraction of oxygen in room air is kept constant at a level of 21%, the global 
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contribution of the peripheral chemoreceptor to total ventilatory response to hypercapnia 
can be evaluated by calculating eVHR minus hVHR (eVHR-hVHR) (12;14-17). 
In SSc, increased respiratory impedance may be present as a result of ILD, thoracic wall 
involvement or increased flow resistance (2;3;18). However, because we measured eVHR 
and hVHR in a single SSc patient on the same day with a limited time interval, we did 
not consider the respiratory impedance to influence the peripheral chemoreflex loop gain 
(eVHR-hVHR). As a result, the GPCD may be compared between SSc patients and controls, 
irrespective of increased respiratory impedance.
Non-invasive CPET
Symptom-limited, noninvasive incremental CPET (without arterial blood gas sampling) was 
next performed under physician supervision in all SSc patients (19). To evaluate the presence 
of a peripheral chemoreflex drive during exercise, we monitored minute ventilation (VdotE) 
and VdotE/VdotCO2 continuously by breath-by-breath analysis. The anaerobic threshold 
was determined by use of the lowest ventilatory equivalent for oxygen (VdotE/VdotO2) or 
the V-slope method whenever appropriate (19). Normally, when exercise continues until 
the occurrence of metabolic acidosis (i.e. at the end of the isocapnic buffer phase), a sharp 
increase in VdotE/VdotCO2 provides ventilatory compensation which reflects an active 
peripheral chemoreflex drive (Figure 6.1). In all CPET results, this response was scored 
qualitatively as being either present or absent (6;10). Since this response is expected in all 
healthy controls, they did not undergo CPET. 
Statistical analysis
Statistical analysis was performed with the SPSS 20.0 package (SPSS, Inc., Chicago, IL, USA). 
Continuous variables are expressed as the mean value ± standard deviation. P-values <0.05 
were considered significant. Categorical data are presented as frequencies and percentages. 
Statistical comparisons were performed by using the Student’s t-test for continuous variables 
and the chi-square test for binary variables.   





Our 49 SSc patients were extensively characterized (Table 6.1). LcSSc patients (n=20) differed 
significantly from patients with dcSSc (n=29) with respect to disease duration, duration of 
skin disease, modified Rodnan skin score, onset of Raynaud phenomenon, and current and 
previous treatment. 
Pulmonary function tests
DcSSc patients differed significantly from lcSSc patients in predicted forced vital capacity 
(FVC%; p=0.034) and total lung capacity, helium dilution method (TLC-He%; p=0.034) 
(Table 6.2). Furthermore, gas transfer (DLCO single breath method) was impaired in both 
groups, although it was not significantly different. These parameters may indicate the 
presence of increased respiratory impedance and therefore ILD, PH or both. 
Figure 6.1 Example of a sharp increase (arrow) in the ventilatory equivalent for CO2, providing ventilatory 
compensation for metabolic acidosis in a single patient with systemic sclerosis. 
EqO2, ventilatory equivalent for O2; EqCO2, ventilator equivalent for CO2.
Chapter_6_Maarten.indd   108 26-10-2015   11:36:12
The global peripheral chemoreflex drive in SSc patients: a rebreathing and exercise study
109
6







Sex, female, no. (%) 18 (90) 18 (62) 16 (50) 0.35






















Disease duration, years, median (IQR) 10.1 (8.1) 4.7 (4.5) - 0.009
Skin duration, years, median (IQR) 11.7 (9.3) 6.1 (6.4) - 0.022
Onset of Raynaud phenomenon, 
months, median (IQR)
14.8 (11.2) 8.5 (8.9) - 0.039
MRSS (0–51), mean (SD) 3.9 (4.1) 7.8 (6.8) - 0.003






























SSc, systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; 
SD, standard deviation; IQR, interquartile range; MRSS, modified Rodnan skin score. * Chi square, Student t-test, 
Mann Whitney U test or Fisher exact test where appropriate between limited and diffuse SSc.







FVC (% pred) 101 (21) 84 (20) - 0.034*
DLCOcSB (% pred) 63 (19) 57 (15) - 0.19*
TLC-He (% pred) 91 (21) 80 (16) - 0.034*
eVHR 2.59 (1.27) 1.87 (0.75) 3.08 (0.75) <0.001#
hVHR 1.70 (0.98) 1.41 (0.62) 2.46 (0.91) <0.001#
eVHR-hVHR 0.90 (0.77) 0.47 (0.38) 0.90 (0.49) 0.04#$
* P-value expressed for Student t-test between lcSSc and dcSSc. # P-value expressed for Student t-test between 
dcSSc and controls. $ P-value expressed for Student t-test between lcSSc and dcSSc. lcSSc, limited cutaneous 
systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity (L); % pred, percentage 
predicted; DLCOcSB, carbon monoxide gas transfer factor corrected for hemoglobin, single breath method 
(mmol/min/kPa); TLC-He, total lung capacity, helium-dilution method (L); eVHR, euoxic ventilatory response 
to hypercapnia (L/min/mmHg); hVHR, hyperoxic ventilatory response to hypercapnia (L/min/mmHg); eVHR-
hVHR, global peripheral chemoreflex drive (L/min/mmHg).
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Euoxic and hyperoxic ventilatory response to hypercapnia
In healthy controls, the mean eVHR was 3.08±0.75 L/min/mmHg and differed significantly 
from that in dcSSc patients (1.87±0.75 L/min/mmHg; p<0.001). Similarly, the mean hVHR 
in controls differed significantly from that in dcSSc patients (2.46±0.91 versus 1.41±0.62 L/
min/mmHg; p<0.001), but not from that in lcSSc patients (1.70±0.98 L/min/mmHg; p=0.11). 
Global peripheral chemoreflex drive (eVHR-hVHR) in dcSSc patients was diminished 
and differed significantly from that in lcSSc patients (0.47±0.38 in dcSSc versus 0.90±0.77 
in lcSSc; p=0.04) and from that in healthy controls (0.47±0.38 in dcSSc versus 0.90±0.49 
L/min/mmHg in healthy controls; p=0.03). Figure 6.2 presents the mean (eVHR-hVHR) 
response in all subjects. 
Furthermore, in 14 of 29 (48%) dcSSc patients, previous treatment consisted of autologous 
hematopoietic stem cell transplantation, which had a significant impact on the modified 
Rodnan skin score and on Raynaud phenomenon. In 15 dcSSc patients who were not treated 
with stem cells, the GPCD was significantly diminished compared with 14 stem-cell-treated 
dcSSc patients (0.27±0.23 and 0.64±0.42 L/min/mmHg, respectively, p=0.008). 
Figure 6.2 Mean (eVHR-hVHR) response to hypercapnia in L/min/mmHg in all subjects. 
eVHR, euoxic ventilatory response to hypercapnia; hVHR, hyperoxic response to hypercapnia; dcSSc, diffuse 
cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis.
Non-invasive CPET
In total, 45 SSc patients (20 lcSSc, 25 dcSSc) reached metabolic acidosis during incremental 
exercise (end of isocapnic buffer phase). Four SSc patients (all dcSSc) discontinued their 
exercise before reaching anaerobic threshold and reported exertional dyspnea. In all CPET 
results for these 45 SSc patients, ventilatory compensation to metabolic acidosis occurred 
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by means of a sharp increase in VdotE and VdotE/VdotCO2 (i.e. Figure 6.1, data not shown) 
(19). Within these 45 SSc patients, peak aerobic capacity (VdotO2peak), a parameter of exercise 
tolerance, did not differ between lcSSc and dcSSc patients (data not shown).
Discussion
In progressive SSc, the global peripheral chemoreflex drive may be altered. Our results 
show the presence of an active peripheral chemoreflex drive during maximal exercise in all 
patients with SSc, as indicated by ventilatory compensation for metabolic acidosis. However, 
the global peripheral chemoreflex drive, as measured by the difference in eVHR and hVHR, 
was diminished in our dcSSc patients compared with that in healthy controls. 
This is the first study on the hypercapnic ventilatory response to evaluate the peripheral 
chemoreflex drive in patients with SSc. In the present study, global assessment of CO2 
responsiveness was used to characterize different populations. We used room air in a 
rebreathing bag and kept the inspired fraction of oxygen during the euoxic rebreathing test 
constant at a level of 21% (12). However, some considerations may apply to the methods 
used in the present study. First, age, sex, status of menstrual phase and ethnicity all affect the 
ventilatory response to CO2 (20). In our study, age and sex were not significantly different 
between SSc patients and healthy subjects. Furthermore, the ventilatory response did not 
significantly differ between healthy male and female SSc patients in the eVHR and hVHR 
tests (data not shown). Therefore, taking these results together, we believe that these issues 
did not contribute significantly to differences in ventilatory responses. Second, some 
dcSSc patients were previously treated with high-dose cyclophosphamide and autologous 
hematopoietic stem cell transplantation. Such treatment was not given to patients with lcSSc 
and may have contributed to the variability in ventilatory responses. 
We used the concept of testing the GPCD by subtracting ventilatory responses to different 
oxygen supplies, as previously suggested by Duffin (17). In mammals, the carotid bodies are 
responsible for 95% of the ventilatory response to hypoxemia (21) and 30% of the response 
to arterial hypercapnia. In patients with resected bilateral carotid bodies, a 20–40% decrease 
in ventilatory response to euoxic hypercapnia is observed (10) Under euoxia, the peripheral 
chemoreflex drive is less active than when measured under hypoxia and considered to be 
50–80% of total peripheral chemoreceptor sensitivity (10;15;16;20). In a previous study, 
we evaluated the peripheral chemoreflex drive in paraganglioma patients by subtracting 
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the hyperoxic from the euoxic ventilatory response to CO2 (11). Furthermore, by using 
different levels of oxygen it was possible to determine the quantitative contribution of the 
chemoreceptors to ventilation at different levels of peripheral chemoreceptor stimulation 
(16;22). Consequently, the GPCD to CO2 could be estimated from the difference in the 
euoxic and hyperoxic slopes (11;15-17). We therefore designated peripheral chemoreflex 
sensitivity under euoxia minus the hyperoxic ventilatory response (eVHR-hVHR) as the 
global peripheral chemoreflex drive.
In the setting of ILD or PH, minute ventilation may be strongly influenced by increased 
respiratory impedance (i.e. reduced respiratory compliance and/or increased flow resistance). 
In our study, lcSSc and dcSSc patients differed significantly in global peripheral chemoreflex 
function. Moreover, since both eVHR and hVHR are measured in the same patient and within 
a limited time period, respiratory impedance is considered not to influence the peripheral 
chemoreflex loop gain (eVHR-hVHR). Therefore, a difference in the GPCD between lcSSc 
and dcSSc patients may be derived from our rebreathing studies. 
In addition to its measurement during rebreathing studies, the peripheral chemoreflex 
function can be assessed during exercise (6;10). When the exercise work rate is high enough 
to produce metabolic acidosis, the increase in ventilatory response is only – and strongly – 
mediated by the peripheral chemoreceptors (6). Thus, in the setting of an absent carotid 
body function, respiratory compensation for metabolic acidosis does not occur (6;10). In 
all of our SSc patients, including dcSSc patients, a ventilatory compensatory response at 
the end of the isocapnic buffer phase occurred as a result of the presence of a peripheral 
chemoreflex drive. However, quantitatively, as our results from the rebreathing studies 
indicate, a diminished ventilatory response is present in dcSSc patients compared with 
that in healthy controls, suggesting an altered GPCD in the absence of metabolic acidosis. 
Our results may be explained by two mechanisms. First, SSc is considered to be an inflam-
matory disease (8;9). Anti-inflammatory treatment by autologous stem cell transplantation 
may have reduced the level of inflammation in carotid bodies, as indicated by our results 
in dcSSc patients. In dcSSc patients treated with autologous hematopoietic stem cell 
transplantation, a significant difference was present in the GPCD compared with that in 
dcSSc patients without such treatment. Therefore, this drive may have been altered positively 
by stem cell transplantation, suggesting an impact on carotid body vascularization and 
consequently its function. Second, widespread atherosclerosis is present not only in lcSSc 
patients, but also in dcSSc patients, and may involve the carotid arteries and bodies (8;9). 
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In subjects affected by widespread atherosclerosis, carotid body parenchyma may show 
degenerative changes; we speculate that atrophy may influence carotid body function (i.e. 
peripheral chemoreceptors) (7-9). We did not, however, measure carotid artery intima 
thickness. Furthermore, serum lipid spectrum was not significantly different between lcSSc 
and dcSSc patients. 
Conclusions
In summary, our results show that in all SSc patients, ventilatory compensation for metabolic 
acidosis occurs as a result of an active peripheral chemoreflex drive. The global peripheral 
chemoreflex drive was, however, diminished in dcSSc patients compared with that in healthy 
controls, suggesting an altered chemoreflex control of breathing in these patients. This may 
help the clinician to better understand reported exercise intolerance and exertional dyspnea 
in dcSSc patients.
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Introduction: Interstitial lung disease occurs frequently in patients with systemic sclerosis 
(SSc). Quantitative computed tomography (CT) densitometry using the percentile density 
method may provide a sensitive assessment of lung structure for monitoring parenchymal 
damage. Therefore, we aimed to evaluate the optimal percentile density score in SSc by 
quantitative CT densitometry, against pulmonary function.  
Material and methods: We investigated 41 SSc patients by chest CT scan, spirometry and 
gas transfer tests. Lung volumes and the nth percentile density (between 1 and 99%) of the 
entire lungs were calculated from CT histograms. The nth percentile density is defined as 
the threshold value of densities expressed in Hounsfield units. A prerequisite for an optimal 
percentage was its correlation with baseline DLCO % predicted. Two patients showed distinct 
changes in lung function 2 years after baseline. We obtained CT scans from these patients 
and performed progression analysis. 
Results: Regression analysis for the relation between DLCO % predicted and the nth 
percentile density was optimal at 85% (Perc85). There was significant agreement between 
Perc85 and DLCO % predicted (R=-0.49, p=0.001) and FVC % predicted (R=-0.64, p<0.001). 
Two patients showed a marked change in Perc85 over a two year period, but the localisation 
of change differed clearly.  
Conclusions: We identified Perc85 as optimal lung density parameter, which correlated 
significantly with DLCO and FVC, confirming a lung parenchymal structure-function 
relation in SSc. This provides support for future studies to determine whether structural 
changes do precede lung function decline. 
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Clinical risk assessment of organ manifestations in systemic sclerosis (SSc) has revealed that 
interstitial lung disease (ILD) is present in 53% of cases with diffuse cutaneous SSc (dcSSC) 
and in 35% of cases with limited cutaneous SSc (lcSSc) (1). For evaluating the response to 
treatment of ILD, pulmonary function tests (PFTs) such as the diffusion capacity for carbon 
monoxide (DLCO) and forced vital capacity (FVC) are key outcome measures. However, 
these measures are affected by pulmonary vascular changes and chest wall skin stiffening, 
respectively (1). Therefore, more specific measures of lung parenchymal involvement of 
ILD may provide additional structural information.
Currently, chest high-resolution computed tomography (HRCT) is considered the most 
accurate noninvasive imaging method for ILD assessment. Both severity and extent of ILD 
are usually estimated by semi-quantitative scoring of a limited number of cross-sectional 
slices through the lungs (2;3). However, visual scoring has limited reproducibility, be-
cause of its subjective nature, and is time-consuming, thereby constraining the number 
of slices that can be assessed. HRCT data provide a means to quantitatively analyze the 
structure of the whole lung, since inflammation, ground glass opacities and fibrosis can 
be quantified by lung densitometry. Therefore, objective quantitative techniques by CT 
densitometry may provide a more sensitive measurement, similar to what has been proven 
in assessing progression of pulmonary emphysema by the percentile density method (4). 
Since these quantitative techniques are automated, it is feasible to quantify the entire lungs 
instead of only a limited number of slices, with a smaller chance of missing pathological 
changes.
Previously, Camiciotolli et al. (5) reported that lung density histogram parameters are more 
reproducible than visual assessment of HRCT and are more closely related to functional, 
exercise and quality-of-life impairment in SSc. In their evaluation of each patient, they 
calculated the average global density of the lung and included kurtosis and skewness of the 
density histogram of the whole lung. However, this analysis did not provide a single overall 
score for the structure of the lungs and, more importantly, lung density values were not 
corrected for lung volume. In a recent report, the same investigators clearly demonstrated 
the need for volume correction of density parameters (6). By a so-called sponge model (7), 
in which the lungs are considered mass preserving (i.e. the total lung mass is constant dur-
ing breathing), density values can be corrected in a relatively simple calculation. Volume-
corrected lung density parameters calculated by specific software may be useful outcome 
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measures in evaluating the progression of ILD and the response to treatment. Therefore, the 
aim of this study was to identify the optimal volume correction and percentage threshold 
for the percentile density method in SSc.
Material and methods
Patients
We investigated 41 patients with SSc who were referred consecutively to our tertiary 
outpatient targeted multidisciplinary healthcare program. As part of this program, all patients 
underwent, among other tests, PFTs and an HRCT scan of the thorax; they were instructed 
to take their usual medication before scanning. Included patients were classified as lcSSc or 
dcSSc according to Leroy EC et al. (8). The local Medical Ethical Committee approved the 
protocol. Written informed consent was obtained from each patient prior to enrolment. In 
two individual patients PFTs (both FVC and DLCO) significantly changed during clinical 
follow-up. To analyze this we performed additional CT scans.  
Pulmonary function testing
All SSc patients had lung volume, spirometry and gas transfer studies. These PFTs included 
inspiratory vital capacity, total lung capacity, FVC, forced expiratory volume in one second 
and single-breath DLCO. Results are expressed as a percentage of the predicted value (9;10).
Computed tomography
All patients were scanned during full inspiration without contrast enhancement by the same 
CT scanner (Aquilion 64, Toshiba Medical Systems, Otawara, Japan), calibrated according 
to the manufacturer’s guidelines. The standardized protocol comprised the following: tube 
voltage = 120 kVp; tube current = 140 mA without modulation; rotation time = 0.4 sec; 
collimation = 64 x 0.5 mm; helical beam pitch = 0.8. Axial slices were reconstructed for visual 
ILD scoring with 0.5 mm slices with 0.4 mm increment and lung kernel (FC30), and for 
densitometry with 5mm thick slices with an increment of 2.5 mm and smooth kernel (FC03). 
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Images were processed by Pulmo-CMS software (version 2.1, Medis medical imaging 
systems BV, Leiden, the Netherlands) (11). The CT scans were first recalibrated on the basis 
of densities measured in extrathoracic air and blood in the descending aorta (12). After 
automated lung contour detection with user correction options was complete, lung volumes 
and the nth percentile density of the entire lungs were calculated. The nth percentile density is 
defined as the threshold value of densities expressed in Hounsfield units (HU), below which 
n% of all lung voxels in the CT images are distributed (as schematically illustrated in Figure 
7.1). In order to optimize the percentile method, we calculated all percentile densities by 
using percentages between 5% and 95% (Perc5–Perc95) with increments of 5%.
Figure 7.1 Schematic graph of the definition of the nth percentile density. 
A, A normalized histogram of lung densities is shown (i.e., with a total area under the curve of 100%). The 
percentile density threshold is chosen in such a way that a predefined percentage (e.g., n=85) of all lung voxels 
(3D pixels) contains densities lower than the threshold, indicated by the green area. B, Because of interstitial 
lung disease (ILD), certain lung densities increase, causing the normalized histogram to change shape, where 
there are relatively more voxels with higher densities (green curve: normal density distribution; red curve: 
shifted distribution with increased densities). As a result, the percentile density has increased.
Subclinical parenchymal lung disease was previously defined as high attenuation areas (% 
HAAs) within the lung fields having a CT attenuation value between -600 and -260 HU (13). 
For comparison, we therefore performed a similar analysis in our data set of lung densities. 
Finally, an experienced chest radiologist (LK) scored all CT scans visually according to the 
Kazerooni scoring system (3).




Optimization of the percentile density method was based on the correlation between nth 
percentile density and DLCO, which should be as high as possible. This was investigated 
by regression analysis, with DLCO as the dependent variable and one of the nth percentile 
densities as the independent variable. Lung volume was entered as a covariate to correct 
for different lung sizes. The partial correlation coefficient was then plotted against the 
percentage n. The statistical analysis was performed by using SPSS version 20.0.2, with a 
programmability extension for python scripting. The relation between the percentile and 
the correlation coefficient was automatically plotted by using Matplotlib (14).
Using the optimal percentage for the percentile density method, we investigated the cross-
sectional correlations with the remaining lung function parameters. In addition, we studied 
the correlation of % HAA with the cross-sectional DLCO % predicted and FVC % predicted.
Progression map analysis
We noticed distinct changes in the FVC % predicted and DLCO % predicted during clinical 
follow-up of our patient population. Therefore we obtained CT scans from these patients 
and performed a recently published progression analysis between baseline and follow-up 
CT scans (15). Local changes in lung density were computed by progression analysis (15). 
Corresponding locations in the CT scans between baseline and follow-up were obtained by 
non-rigid intensity-based image registration using elastix (16). After we corrected for lung 
volume differences with the sponge model, local changes in lung density were calculated 
and displayed (15).   
Results
The clinical characteristics of the 41 SSc patients (LcSSc: n=15) in this prospective cross-
sectional study are shown in Table 7.1. 
Determination of the optimal percentage
From the regression analysis (with CT-derived lung volume as a covariate), we found that 
the relation between the gas transfer factor DLCO (as % predicted) and the nth percentile 
density was optimal at 85% (Perc85), with a partial correlation coefficient of -0.32, as shown 
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in Figure 7.2. The slope between Perc85 and DLCO was -0.069 (95% confidence interval: 
-1.36 to -0.001).
Relation between structure and function 
In the remainder of this report, Perc85 is used as the optimal parameter. There was a 
moderate agreement between Perc85 and both DLCO % predicted (R=-0.49, p=0.001) and 
FVC % predicted (R=-0.64, p<0.001) (Figure 7.3A and 7.3B, respectively). Kazerooni scores 
correlated significantly with Perc85 (R=0.56, p<0.01). For the alternative densitometric 
method by % HAA, Spearman’s correlation with DLCO % predicted was R=-0.48 (p=0.002) 
and with FVC % predicted was -0.62 (p<0.001). 
Table 7.1 Clinical data of SSc patients
LcSSc DcSSc
Demographic data and serology
Number of patients (n=41) 15 26
Age 54.7 (14.5) 48.7 (11.3)
Sex (female) 11 (73) 20 (83)
Disease duration, years 5.8 (7.4) 4.6 (3.5)
Onset of Raynaud, years 12.7 (11.3) 7.1 (4.8)
Caucasian origin (y/n) 13 (87) 18 (69)
Modified Rodnan skin score 6 (4–9) 9 (5–15)
Number of patients with:
Antinuclear antibodies 14 21 
Anti-centromere antibodies 7 4 
Anti-Scl-70 2 16
Overall treatment
ASCT 0 (0) 9 (22)
Cyclophosphamide 0 (0) 11 (27)
Methotrexate 3 (7) 5 (12)
Rituximab 0 (0) 5 (12)
Mycophenolate – Mofetil 1 (2) 4 (10)
Azathioprine 1 (2) 0 (0)
Pulmonary function
FVC, L 3.34 (0.76) 3.37 (0.99)
FVC, % predicted 104.7 (26.5) 90.7 (19.5)
DLCO, mL/min/mmHg 5.67 (1.23) 6.06 (2.22)
DLCO, % predicted 67.7 (12.4) 64.0 (14.6)
FVC/DLCO 0.67 (0.17) 0.68 (0.19)
Data presented as mean (SD) or as median (25–75th percentile), n (%). LcSSc, limited cutaneous systemic 
sclerosis; DcSSc, diffuse cutaneous systemic sclerosis; ASCT, autologous stem cell transplantation; FVC, forced 
vital capacity; DLCO, single breath diffusion capacity of the lung for carbon monoxide.
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Figure 7.2 Partial correlation between percentile density and DLCO % predicted, against the percentage 
used for defining the percentile density. 
For each percentage, the slope is plotted with 95% confidence intervals (blue error bars). The corresponding 
partial correlation coefficient is indicated by green dots. Lung volume during CT scanning was entered in 
the regression analysis as a covariate.shifted distribution with increased densities). As a result, the percentile 
density has increased.
Prospective application in individual study data: progression map 
analysis
Two isolated individuals in our SSc population showed marked change in their clinical 
course. After the observed change in their FVC (+24 and +8% pred) and DLCO (+11 and 
+5% pred), we decided to image their lungs by a similar CT scan. These data were not part 
of our cross-sectional study. Details of the two patients with diffuse SSc were analyzed 
extensively by local progression analysis (15). Figure 7.4 shows a local decrease lung density 
(in HU) in both patients, albeit in different locations in the lung and with different patterns. 
Both patients had ground glass densities that partly resolved after one year, in patient B this 
returned to the average values of the study population.
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Figure 7.3 Correlation between lung structure and function. 
A, Correlation between volume-corrected 85th percentile density and CO diffusion capacity (R=-0.49, p=0.001). 
B, Correlation between volume-corrected 85th percentile density and forced vital capacity (R=-0.64, p<0.001).
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We studied the lung tissue structure by histogram analysis of lung densities obtained from 
CT images of patients with SSc. We report that the 85th percentile density score (Perc85) 
represents the most informative density parameter to assess lung parenchyma in SSc. Perc85 
significantly correlated with DLCO as a measure of gas transfer. Interestingly, the lower 
percentile densities showed a positive relation between density and DLCO, indicating that 
low lung densities in SSc are accompanied by relatively high gas transfer values. Higher 
percentile densities showed the opposite, i.e., higher lung densities are associated with a 
relatively low gas transfer. This suggests that changes in lung density correlate with clinically 
relevant functional changes in patients with various severities of SSc. Indeed, two cases with 
marked improvement in FVC and DLCO related to a marked decline in Perc85.
The analysis of lung structure by densitometry of CT images provides a rapid and operator-
independent assessment of lung pathology in SSc. Percentile density analysis of the histogram 
of tissue densities for both lungs is new in the analysis of ILD. The Perc85 point contains all 
densities present in the histogram between the density of air (-1000 HU) and the Hounsfield 
unit at which 85% of the densities in the histogram is captured. We considered DLCO 
rather than FVC as the most appropriate functional parameter for determining the optimal 
percentile density, although FVC is the most frequently reported outcome parameter in SSc 
for analysis of ILD (17;18). By using FVC only for the ultimate evaluation of the optimized 
parameter, we avoided introducing bias. Therefore, we calculated the correlation between 
DLCO % predicted of our SSc patients and all percentiles of the density histogram of each 
CT scan, which were corrected for lung volume. Again, this resulted in the 85th percentile 
density as the optimum lung density for analysis of lung structure. 
Interestingly, two patients had a substantial change in both FVC and Perc85. By application 
of recently developed software (15), we demonstrated that areas with a decrease in lung 
density over time can be identified in the lungs, suggesting an improvement in the quality 
of lung tissue, and that these were accompanied by an increase in FVC and DLCO. Data 
from these two patients suggest that small changes in lung density do precede changes in 
their FVC and DLCO. However, assessment of a larger number of patients and a longer 
time interval are needed in future studies to confirm this observation and to evaluate the 
clinical benefit of lung densitometry. 
The present study has some limitations. The range of lung function restriction was rather 
limited. A wider range of lung function restriction is needed to elucidate whether Perc85 will 
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be able to detect changes in lung density over the entire severity spectrum of SSc. Validation 
of lung density against quantitative pathology scores of SSc-affected lung tissue is almost 
impossible. Unlike in pulmonary emphysema, no quantitative pathology score is available 
that can be used in the analysis of lobectomy or pneumonectomy tissue specimens from SSc 
patients (19). However, some studies have used qualitative pathology scores on open lung 
biopsy specimens from ILD patients, and these related significantly to lung HRCT scores 
(3;20). Furthermore, we found that one such score, published by Kazerooni (3), correlated 
significantly with Perc85. The latter may suggest a possible correlation between a pathology 
score and our Perc85 score for lung tissue structure.
Conclusions
We identified an optimal lung density parameter, Perc85, which correlated significantly 
with gas transfer in the lung and may be used to assess clinically relevant changes in lung 
structure that coincide with changes in lung function. Future studies are needed to determine 
whether a change in Perc85 will precede changes in FVC and gas transfer to support clinical 
decision making on early treatment intervention in SSc patients.
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The burden of complicating interstitial lung disease and pulmonary 
vasculopathy in systemic sclerosis
Systemic sclerosis is a clinically heterogeneous, multi-system autoimmune disorder. Patients 
with SSc usually have proliferative small artery and obliterative microvascular disease, 
plus inflammation and fibrosis affecting not only the skin, but importantly, also the lungs. 
Pulmonary involvement is very common in SSc and most often consists of interstitial lung 
disease (ILD) and pulmonary vascular disease leading to pulmonary (arterial) hypertension 
(PAH). These complications of the disease are the leading cause of disease related morbidity 
and mortality (1) and mortality from pulmonary disease in SSc can be as high as 33% (2). 
Clinical signs of pulmonary involvement in SSc may include shortness of breath on exertion 
and, eventually, at rest. Additionally, patients may exhibit a non-productive cough, chest 
pain and dyspnoea. These symptoms are highly prevalent; dyspnoea is present in SSc in 
93% of all cases (3). However, the prevalence of respiratory symptoms has been shown 
to be similar in SSc patients with and without concurrent lung disease (4). Traditionally, 
pulmonary function testing, echocardiography and high-resolution chest CT play a key role 
in the evaluation of dyspnoea and pulmonary complications. Frequently, patients can be 
well characterised using these tests, i.e. into a limited and extensive disease (5;6). However, 
these examinations may not always elucidate subclinical disease. Consequently, there is a 
need for non-invasive (bio)markers of complicating ILD and PAH in SSc, even in subclinical 
cases. Predictive models of major organ complications, in particular the lungs, are essential 
and may be used as clinical tools for patients risk stratification and could facilitate clinical 
interventional studies. In this thesis, several of these (bio)markers are addressed. 
A different approach to dyspnea evaluation at rest and during exercise 
in SSc
Progressive systemic sclerosis may involve ILD and PAH and results into dyspnea at rest and 
on exertion. Dyspnea as a presenting occurs in 20% of all newly diagnosed SSc patients and in 
93% of patients with complicating ILD and/or PAH (3). In all of these patients the mechanics 
of the respiratory system are involved. These mechanics, i.e. the impedance of the respiratory 
system, are influenced by lung and chest wall compliance and respiratory flow resistance (7). An 
increased respiratory impedance is recognized as the most frequent cause of dyspnea. In SSc, 
ILD or limited chest wall excursions cause an increased respiratory impedance. Other causes 
of dyspnea may include hypoxia, respiratory muscle weakness and pulmonary vasculopathy. 




Traditionally, dyspnea is initially evaluated by the pulmonary physician using pulmonary 
function tests (spirometry, carbon monoxide gas transfer studies and body plethysmography) 
(8). However, in SSc, dyspnea may also arise from an inappropriate ventilatory response upon 
the chemoreflex drive at rest and to hypercapnia (9;10). To assess this ventilatory response, 
resting ventilation and tidal volumes can be evaluated. Ventilation, however, is an imperfect 
output parameter of the respiratory drive since it is affected by alterations in the impedance of 
the respiratory system (i.e. mechanical properties of the lung and chest wall). Mouth occlusion 
pressures (MOP, P0.1), as an index output parameter of the respiratory drive, provide not 
only a high reproducibility within each subject but also independency of age and sex (11). In 
all subjects, a relation between resting ventilation and MOP (V’E/P0.1) higher than 8 L/min 
sharply separates a normal from an abnormal response (11). In addition, the respiratory drive 
to hypercapnia (P0.1 to CO2, i.e. ΔP0.1/ΔCO2) provides insight into the central chemoreflex 
drive (9). These simple tests showed in our SSc population a distinct different response 
from normal reported values (Chapter 5, this thesis). Furthermore, an increased respiratory 
impedance could be depicted from our results in contrast to pulmonary function tests, which 
did not show any abnormality. Therefore, MOP at rest and during hypercapnia provide an 
easy to perform initial screening test in patients with SSc complaining of dyspnea. 
In addition to mouth occlusion pressures and the measurement of the central chemoreflex 
drive, the peripheral chemoreflex drive plays an important role in resting ventilation and 
during exercise (12;13). Exercise intolerance in systemic sclerosis is a determinant of 
the disease and has a major impact on the quality of life (14). Moreover, the peripheral 
chemoreflex plays an important role in the control of breathing at rest and during exercise 
(15;16). Reported dyspnea at rest and during exercise may not only influenced by an increased 
respiratory impedance, but also by a diminished peripheral chemoreflex drive. This drive 
may be assessed by the difference between the ventilatory response to hypercapnia under 
euoxic (eVHR) and hyperoxic conditions (hVHR), i.e. eVHR-hVHR (Chapter 6 this thesis) 
and in addition, by cardiopulmonary exercise testing (CPET). In the latter, the occurrence 
of an ventilatory response in the setting of metabolic acidosis represents an active peripheral 
chemoreflex drive (16). In SSc, the peripheral chemoreflex drive showed to be significantly 
different between patients with limited cutaneous SSc and diffuse cutaneous SSc. Possible 
explanations include the reduction in the level of inflammation in by autologous stem-cell 
transplantation in a subgroup of diffuse cutaneous SSc patients (17) consequently affecting 
the carotid body vascularization and its function. Secondly, carotid body parenchyma may 
be negatively affected by the well-known widespread atherosclerosis in SSc (18-20). 
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Dyspnea evaluation in SSc can be challenging, in particular when both ILD and PAH are 
present. However, simple tests to detect whether the mechanical properties of the respiratory 
system are involved are necessary to guide further examination. Furthermore, these tests as 
described in Chapter 5 and 6 are even applicable in the most severely affected SSc patients 
who cannot produce reliable flow-volume curves. We therefore advocate the use of these 
tests early in clinical practice, not as a replacement of spirometry and gas transfer studies, 
but more as complementary, in order to facilitate best personalized medicine.   
Analysis of non-invasive resting and exercise physiology to detect pul-
monary vasculopathy in SSc
Recently, two-dimensional (2-D) speckle tracking strain analysis was proposed as a sensitive 
and accurate method for the evaluation of subclinical myocardial dysfunction (21). In short, 
this technique allows the assessment of left ventricular (LV) and right ventricular (RV) 
myocardial deformation by tracking the acoustic markers (speckles) in a frame-to-frame basis 
within the cardiac cycle (22). In Chapter 3 and 4 this technique is applied in SSc patients in 
whom subclinical cardiovascular involvement can occur in up to 70% (23). Concerning the 
left, ventricle 2-D speckle strain analysis revealed LV systolic dysfunction despite normal 
LV ejection fraction and normal LV dimensions. Furthermore, LV global longitudinal 
and circumferential strains were independently associated with oxygen uptake. This study 
demonstrated that LV global longitudinal and circumferential strains were significantly 
correlated with maximum aerobic capacity (VO2% predicted), independent of age, SSc subtype, 
and lung function. Thus, this observation indirectly provided evidence that LV dysfunction 
contributes to an impaired functional capacity in patients with SSc. This novel technique 
therefore represents a valuable tool to improve the risk stratification among SSc patients. 
In the RV study (the evaluation of RV dysfunction in relation to pulmonary hypertension 
and pulmonary fibrosis in SSc patients), free wall strain was significantly impaired in patients 
with SSc compared to controls. In particular patients with pulmonary fibrosis and ILD 
showed the most impaired free wall strain. A potential explanation for the findings in the RV 
study is that pulmonary fibrosis may be associated with mild/latent or dynamic pulmonary 
hypertension, which could not be detected by a single echocardiographic measurement 
(24). In addition, patients with pulmonary fibrosis have been shown to be more likely to 
have systemic involvement, and are therefore probably at higher risk for a significant direct 
myocardial involvement contributing to RV dysfunction (25). 




In addition to echocardiographic studies, chapter 5 has a focus on the contribution to risk 
stratification among SSc patients by analysing the oxygen pulse slope in a cardiopulmonary 
exercise test (CPET). The oxygen pulse, which normalizes oxygen consumption for heart 
rate, is widely used as an indirect measurement for cardiac stroke volume (SV) (26) and 
is correlated with invasively measured SV (27). In SSc, a novel analysis of the V’O2/HR 
slope to exercise in the clinical evaluation of systemic sclerosis patients showed that a 
breakpoint in the V’O2/HR slope was preceded by a breakpoint in the slope of pulmonary 
arterial pressures against oxygen uptake. This suggests that the increase in pulmonary 
pressures results in a change in heart rate response to maintain sufficient cardiac output. 
In patients with a breakpoint in the V’O2/HR slope, peak oxygen uptake was limited and 
differed significantly compared to patients without a breakpoint. Importantly, in patients 
with normal SPAP at rest, non-invasive CPET identified patients with a V’O2/HR slope not 
fitting in the normal range (i.e. pathologic V’O2/HR slope). In the evaluation of SSc patients, 
analysis of the V’O2/HR slope may therefore reveal important information extending that of 
Doppler echocardiography in resting patients. Taken together, these patients may be at risk 
for developing pulmonary vasculopathy and ultimately pulmonary hypertension.
In patients with exercise induced pulmonary hypertension (EIPAH), two different groups 
were defined by the nature of their mPAP response to exercise (28). Data during exercise 
were analyzed using best-fit two-segment plots of mPAP versus oxygen uptake. Patients with 
severe EIPAH and resting PAH showed a “plateau” physiology. In these patients mPAP will 
increase as well as PVR during exercise until the cardiac output is compromised and starts to 
fall. Eventually, with a decline in cardiac output as a result of right ventricular dysfunction, 
PAP will not further increase or even fall resulting in a compensatory tachycardia. In contrast, 
patients with mild to moderate EIPAH showed a “take-off” physiology, suggesting pulmonary 
vasoconstriction during incremental exercise (28;29). In these patients, mPAP further 
increases in which the cardiac output does not decrease. Therefore, it seems plausible that 
patients with PAH of varying duration and severity will exhibit different mPAP responses to 
exercise. Likewise, different comparable V’O2/HR slopes may be expected in these patients. 
Since different mPAP responses in patients with varying PAH or EIPAH are present, different 
V’O2/HR responses are likely to occur. In other words, pulmonary vasculopathy, as reflected 
by a sudden increase in pulmonary pressures, may result into a breakpoint in the V’O2/HR 
slope during non-invasive CPET. Consequently, the pulmonary vasculature may be more 
affected in patients showing a pathologic V’O2/HR slope compared to patients without a 
pathologic V’O2/HR slope. 
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Our novel analysis of the V’O2/HR slope showed that SSc patients with a breakpoint in 
this slope are characterized by a decreased oxygen uptake and exercise capacity. This 
breakpoint is preceded by a sudden increase in pulmonary arterial pressures and may 
therefore reflect an inadequate increase or even decrease in stroke volumes. Importantly, 
non-invasive CPET identified patients with a pathologic V’O2/HR slope despite normal 
echocardiographic pulmonary pressures at rest. These patients may have a compromised 
pulmonary vasculature and are at risk for developing pulmonary vasculopathy and ultimately 
pulmonary hypertension. To assess the predictive value of the V’O2/HR breakpoint analysis, 
analysis of serial CPET and echocardiography in patients with normal SPAP and a pathologic 
V’O2/HR slope or with a V’O2/HR breakpoint are needed. Our analysis implies the analysis of 
the V’O2/HR slope in every newly diagnosed SSc patient. Since a compromised pulmonary 
vasculature is not restricted to systemic sclerosis, our novel analysis may also be applicable 
to other types of lung disease coinciding with cardiovascular malfunction.
Lung densitometry as a quantitative measurement for interstitial lung 
disease assessment
The analysis of lung structure by densitometry of CT images provides a rapid and an 
operator-independent assessment of lung pathology. In our SSc population, the 85th percentile 
density score (Perc85) represented the most informative density parameter to assess lung 
parenchyma in SSc. It significantly correlated with DLCO, suggesting that changes in lung 
density correlate with clinical relevant functional changes in patients. In particular, two 
patients showed a substantial change in both their FVC and Perc85. By the application 
of specific software, progression maps were made showing areas with a decrease in lung 
density over time. These decreases were accompanied by increases in FVC. Interestingly, lung 
densitometry may show changes in lung density which may precede changes in functional 
parameters such as FVC. Since HRCT is considered the most accurate non-invasive imaging 
method for ILD assessment, quantitative assessment tools are necessary. However, only semi-
quantitative scoring methods are currently used to determine the severity and extent of ILD. 
Visual scoring has limited reproducibility and is time-consuming (5;30). A quantitative tool 
may help the clinician to decide which patient will benefit from a treatment intervention. 
Furthermore, it allows treatment evaluation and early clinical decision making. 




Conclusions and future perspectives
Recent cohort studies have demonstrated an improvement in the overall survival among SSc 
patients who were analysed for pulmonary involvement in a standardized manner (1;31). 
More recent cohorts showed reduced mortality and better disease outcome. Steen et al. 
analysed mortality and causes of death among SSc patients studied in a single centre dividing 
the subjects into groups based on the 5-year time periods between 1972 and 1997 within 
which they had their first assessment (1). Ten year survival from disease diagnosis showed 
improvement from 54% in the 1972–76 group to 66% in the 1987–91 group. In addition, 
systematic annual screening of organ-based complications and greater awareness of these 
manifestations has substantially increased accurate organ ascertainment and improved 
survival. Therefore we hope that the assessment methods and techniques presented in this 
thesis may better help the clinician if and when to start with immunomodulating agents 
and/or stem cell transplantation in SSc. 
This thesis has focused on the relation between pulmonary structural abnormalities and 
its relation with pulmonary and cardiac function tests. Better ascertainment of lung and 
cardiac involvement is of particular interest, since treatment allocation has been traditionally 
based on the extent and type of its involvement. We showed that novel speckle tracking 
echocardiography can detect subtle myocardial abnormalities and has highly correlated 
with reduced aerobic capacity and the presence of pulmonary hypertension with or without 
ILD. Secondly, we demonstrated that during exercise our novel analysis of the oxygen pulse 
slope revealed clearly the onset of a sudden increase in pulmonary pressures which were 
also highly correlated with aerobic capacity and therefore survival. Finally, we presented 
a novel technique in the assessment of CT images, providing a quantitative, reproducible 
manner to evaluate the extent of SSc associated ILD.  
Current evaluations of therapies focus on patient survival or markers of chronic disease 
progression (e.g. change in FVC). However, therapeutic research has been limited by the 
lack of consensus on and the validation of outcome measures that reliably assess treatment 
response. The outcome measures in Rheumatology (OMERACT) filter is a dynamic 
structure through which an instrument’s performance can be evaluated under three 
points of examination: validity, discrimination and feasibility (32;33). Changes in FVC, 
as an example, have been shown to be reproducible in SSc-ILD but not in other forms of 
connective tissue related- ILD (CTD-ILD) (34). There are confounding issues of (pulmonary) 
vasculopathy, chest wall impairment and systemic disease activity that may coexist in CTD-
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ILD. Nevertheless, FVC remains a reliable and sensitive parameter to reflect the contribution 
of parenchymal disease. 
Although cohort studies remain a cornerstone in studying outcome of rare and heterogeneous 
diseases such as SSc, they should ideally be contemporary with prospective standardized 
data collection. This has significant implications for the cost and utility of descriptive 
clinical research. As such, the novel techniques described in this thesis may contribute to 
better identification of SSc patients at risk for developing clinically important pulmonary 
and cardiac complications. This would facilitate the clinician in clinical decision making 
and treatment evaluation in a “personalized care setting” for the SSc patient. However, since 
clinical research always evolves future studies on the organ ascertainment may include an 
integral analysis of all rest and exercise parameters involved in the detection of PH and ILD. In 
addition, the predictive value of quantitative CT densitometry (evaluating lung parenchyma 
and vessels) on the change in pulmonary and cardiac function tests is of particular interest. 
Therefore, we aim to focus on these themes in the coming years.
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Chapter 9




This thesis describes the clinical assessment of complicating interstitial lung disease (ILD) 
and pulmonary vasculopathy (PV) in patients with systemic sclerosis (SSc). In chapter 2, 3 
and 4 exercise test derived and echocardiographic parameters for the presence of ILD and/
or PV are described. In chapter 5 and 6 patient-reported dyspnea and exercise intolerance 
are studied and in chapter 7 lung densitometry is performed to assess the lung function-
structure relationship in SSc. 
Systemic sclerosis is a systemic autoimmune disease that is characterised by endothelial 
dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with resultant 
excessive collagen production and fibrosis. The classification of SSc is based on the extent 
of skin involvement into diffuse cutaneous sclerosis (dcSSc) and limited cutaneous sclerosis 
(lcSSc). While virtually any organ system may be involved in the disease process, fibrotic 
and vascular pulmonary manifestations of SSc, including ILD and pulmonary hypertension 
(PH), are the leading cause of death. Better ascertainment of lung and cardiac involvement 
is of particular interest, since treatment allocation has been traditionally based on the extent 
and type of its involvement.
In chapter 2 the oxygen pulse slope (V’O2/HR) is studied in patients with SSc during 
cardiopulmonary exercise testing (CPET). The oxygen pulse normalizes oxygen consumption 
for heart rate and is widely used as an indirect measurement of cardiac stroke volume (SV). In 
our experience, SSc patients may show an abnormal V’O2/HR slope containing a breakpoint 
despite normal pulmonary pressures measured at rest using Doppler echocardiography 
(DE). We hypothesized that a compromised pulmonary vasculature may lead to an increase 
in pulmonary pressures and an decreased oxygen uptake. The resulting heart rate increase 
as a function of the oxygen uptake (V’O2/HR) may therefore show a breakpoint in the slope 
reflecting a disproportional heart rate increase. In two SSc patient populations (Graz, Austria 
and Leiden, the Netherlands) V’O2/HR slopes were analysed for breakpoints. In the Austrian SSc 
population simultaneous right heart catheterisation was performed allowing direct comparison 
between heart rate and pulmonary pressure increase as a function of oxygen uptake during 
exercise. In the Austrian CPETS a breakpoint in the V’O2/mPAP preceded the breakpoint in 
the V’O2/HR slope. In the Leiden CPETs peak oxygen uptake was significantly lower CPETs 
containing a V’O2/HR breakpoint. Furthermore, several pathologic V’O2/HR slopes were 
observed despite normal resting pulmonary pressures measured by DE. Whether these patients 
will develop pulmonary hypertension at rest is an interesting focus for further research. 




Chapter 3 and 4 describe the use of a new available echocardiographic tool to assess 
the myocardial velocity and deformation (strain) by tissue Doppler imaging. This two-
dimensional speckle-tracking strain analysis has been proposed for the evaluation of 
left ventricular (LV) regional and global strain in 3 orthogonal directions (longitudinal, 
circumferential and radial). Right ventricular (RV) function was assessed by speckle-
tracking derived RV free wall strain. The relation between LV systolic dysfunction as 
measured by this technique and functional capacity (peak oxygen uptake during CPET) as 
well as ventricular arrhythmias was evaluated in chapter 3. Each strain was independently 
associated with peak oxygen uptake. Furthermore each strain was associated with abnormal 
Holter electrocardiography results. In chapter 4 the potential role of pulmonary fibrosis 
and pulmonary hypertension (PHT) in the development of RV dysfunction was evaluated. 
Compared to controls SSc patients without pulmonary fibrosis and PHT had an impaired 
RV free wall strain. Both pulmonary fibrosis and PHT were independently associated with 
impaired RV free wall strain and therefore RV dysfunction. The findings of both LV and 
RV strain analysis in SSc should be explored in larger prospective studies to assess the 
prognostic value of these measures. 
In chapter 5 and 6 frequently reported problems by SSc patients are described: dyspnea and 
exercise intolerance. Dyspnea may arise in SSc by complicating interstitial lung disease and/
or pulmonary hypertension. An increased respiratory impedance, which is influenced by 
the lung and chest wall compliance as well as respiratory flow resistance, is recognized as the 
most frequent cause of dyspnea. To assess dyspnea in SSc, mouth occlusion pressures as an 
index of central respiratory output (i.e. the respiratory drive), were measured in chapter 5. In 
addition, they were obtained during CO2 rebreathing and related to pulmonary function tests. 
Normal values of mouth occlusion pressures (V’E/P0.1>8 l/min/cm H2O) are independent 
of age and sex. Furthermore, the technique has a high reproducibility within each subject. 
In SSc patients an abnormal V’E/P0.1 response provided a better correlation with severity 
of dyspnea than traditional lung function parameters. Furthermore, in these patients, 
∆P0.1/∆PetCO2, as an index of the central chemoreceptor response to hypercapnia, was 
significantly higher than in SSc patients with normal mouth occlusion pressure responses. 
Since it sharply demarcates a normal from a high (i.e. abnormal) impedance of the respiratory 
system, mouth occlusion pressures (V’E/P0.1) can be easily assess as a first diagnostic test 
in the outpatient clinic. In chapter 6 the peripheral chemoreflex drive is studied in SSc in 
relation to patient-reported exercise intolerance. The peripheral chemoreflex drive plays 
an important role in the control of breathing at rest and during exercise. Activation of this 
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drive has been implicated in the ventilatory compensation for metabolic acidosis during 
exercise. This activation is reflected by an sharp increase in the ventilator equivalent for 
CO2 at the end of the isocapnic buffer phase and decrease in end-tidal pCO2. In addition 
to an exercise test, the peripheral chemoreflex drive is assessed by the difference between 
the euoxic and hyperoxic ventilatory response to hypercapnia (eVHR-hVHR). Since SSc is 
primarily a microvascular disorder, SSc-related inflammatory and fibrotic responses in the 
carotid body may cause a diminished peripheral chemoreflex. In all SSc patients, respiratory 
compensation for metabolic acidosis occurred. However, eVHR-hVHR differed significantly 
between limited cutaneous and diffuse cutaneous patients, suggesting an altered control 
of breathing in these patients. This may help the clinician to better understand reported 
exercise intolerance and exertional dyspnea in diffuse cutaneous SSc patients. 
In chapter 7 lung structure and lung function relationship is studied by lung densitometry 
and pulmonary function tests. Data from a high-relation CT scan of the thorax (HRCT) 
provide a means to quantitatively analyze the structure of the whole lung, since inflammation, 
ground glass opacities and fibrosis can be quantified by lung densitometry. Therefore, objec-
tive quantitative techniques by CT densitometry may provide a more sensitive measurement 
than visual scoring as currently is done by the radiologist. In SSc, we evaluated the optimal 
percentile density score in SSc by quantitative CT densitometry, against pulmonary function. 
Lung volumes and the nth percentile density (between 1 and 99%) of the entire lungs were 
calculated from CT histograms. The nth percentile density is defined as the threshold value 
of densities expressed in Hounsfield units. A prerequisite for an optimal percentage was its 
correlation with baseline DLCO% predicted. Regression analysis for the relation between 
DLCO% predicted and the nth percentile density was optimal at 85% (Perc85). There was 
significant agreement between Perc85 and DLCO % predicted and FVC % predicted. Of 
interest, two patients showed a marked change in Perc85 over a two year period, but the 
localisation of change differed clearly. We conclude that we identified Perc85 as optimal lung 
density parameter, which correlated significantly with DLCO and FVC, confirming a lung 
parenchymal structure-function relation in SSc. This provides support for future studies to 
determine whether structural changes do precede lung function decline.
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Samenvatting




Dit proefschrift beschrijft de klinische evaluatie van complicerende interstitiële longaandoe­
ningen (ILD) en pulmonale vasculopathie (PV) bij patiënten met systemische sclerose (SSc). 
In hoofdstuk 2, 3 en 4 worden parameters beschreven voor de aanwezigheid van ILD en/of 
PV, afgeleid uit een inspanningstest en een echo cor. In hoofdstuk 5 en 6worden patiënt­
gerapporteerde kortademigheid en inspanningsintolerantie beschreven en in hoofdstuk 7 
wordt longdensitometrie toegepast om de longfunctiestructuurrelatie in SSc beoordelen.
Systemische sclerose is een auto­immuunziekte die wordt gekenmerkt door endotheliale 
disfunctie resulterend in een vasculopathie die met name de kleinere vaten betreft. Voorts 
is er een fibroblastdysfunctie met als resultaat excessieve collageendepositie en interstitiële 
fibrose. De classificatie van SSc is gebaseerd op de mate van aangedaan huidoppervlak en 
wordt onderverdeeld in diffuse cutane sclerose (dcSSc) en beperkte cutane sclerose (lcSSc). 
Hoewel vrijwel elk orgaansysteem betrokken kan zijn bij het ziekteproces, zijn fibrotische 
en pulmonaire vasculaire uitingen van SSc (ILD en pulmonaire hypertensie (PH)), de 
voornaamste doodsoorzaak. Betere evaluatie van pulmonale en cardiale betrokkenheid is 
van bijzonder belang, omdat het besluit om te behandelen van oudsher gebaseerd is op de 
omvang en de aard van deze betrokkenheid.
In hoofdstuk 2 wordt de zuurstofpolshelling (V’O2/HR) onderzocht bij patiënten met SSc 
gedurende een cardiopulmonale inspanningstest (CPET). De zuurstofpols normaliseert 
zuurstofverbruik voor de hartslag en wordt veel gebruikt als een indirecte meting van het 
slagvolume (SV). In onze ervaring, kunnen SSc­patiënten een abnormale V’O2/HR­helling met 
een breekpunt hebben, ondanks normale pulmonaaldrukken gemeten in rust met behulp van 
Doppler echocardiografie (DE). Onze hypothese was dat een gecompromitteerde pulmonale 
vasculatuur kan leiden tot een toename van pulmonaaldrukken en een verminderde 
zuurstofopname. De hartslagtoename als een functie van de zuurstofopname (V’O2/HR) kan 
dan ook een breekpunt in de helling bevatten, hetgeen een disproportionele hartslagtoename 
weerspiegelt. In twee SSc­patiëntpopulaties (Graz, Oostenrijk en Leiden, Nederland) werden 
V’O2/HR­hellingen geanalyseerd op breekpunten. In de Oostenrijkse SSc­populatie werd 
gelijktijdig een rechtse hartkatheterisatie uitgevoerd waardoor een directe vergelijking 
tussen de hartslag en de pulmonale drukverhoging als functie van de zuurstofopname 
tijdens inspanning mogelijk werd. In de Oostenrijkse CPET’s viel bijzonder op dat een 
breekpunt in de V’O2/mPAP­helling een breekpunt in de V’O2/HR­helling voorafging. In 
de Leidse SSc­populatie bleek de piek­zuurstofopname aanzienlijk lager in CPET’s waarin 




zich een V’O2/HR­breekpunt bevond. Verder werden verschillende pathologische V’O2/
HR­hellingen (V’O2/HR­helling buiten het normale bereik) waargenomen ondanks normale 
rust­ pulmonaaldrukken gemeten door DE. Of deze patiënten pulmonale hypertensie in 
rust ontwikkelen, vormt een interessant focus voor verder onderzoek.
Hoofdstuk 3 en 4 beschrijven het gebruik van een nieuw beschikbaar echocardiografisch 
instrument voor het meten van myocardiale vervorming (strain) door middel van een 
echo cor. Deze tweedimensionale “speckle­tracking” strainanalyse voor de evaluatie 
van de linkerventrikel (LV) bekijkt de regionale en globale strain in drie orthogonale 
richtingen (longitudinaal, circumferentieel en radiair). De rechterventrikelfunctie (RV) 
werd beoordeeld door de “speckle­tracking” strainanalyse van de RV vrije wand. De relatie 
tussen LV systolische dysfunctie, gemeten met deze techniek, en functionele capaciteit (piek­
zuurstofopname tijdens CPET) en ventriculaire aritmieën werd geëvalueerd in hoofdstuk 3. 
Elke strain bleek onafhankelijk geassocieerd met de piek­zuurstofopname. Bovendien was 
elke strain geassocieerd met abnormale Holter­elektrocardiografie resultaten. In hoofdstuk 
4 werd de potentiële rol van longfibrose en pulmonale hypertensie (PHT) in de ontwikkeling 
van RV­dysfunctie geëvalueerd. Vergeleken met controles hadden SSc­patiënten zonder 
longfibrose en PHT een verminderde strain van de RV vrije wand. Zowel longfibrose als 
PHT waren onafhankelijk geassocieerd met een verminderde strain van de RV vrije wand 
en dus RV­dysfunctie. De bevindingen van zowel de LV­ als RV­strainanalyse in SSc moeten 
worden onderzocht in grotere prospectieve studies om de voorspellende waarde van deze 
metingen te kunnen beoordelen.
In hoofdstuk 5 en 6 worden frequent, door SSc­patiënten gemelde, klachten beschreven: 
kortademigheid en inspanningsintolerantie. Kortademigheid kan ontstaan in SSc door 
complicerende interstitiële longaandoeningen en/of pulmonale hypertensie. Een toegenomen 
pulmonale impedantie, die wordt beïnvloed door de weerstand van long en borstwand en 
respiratoire luchtstromingsweerstand, wordt erkend als de meest voorkomende oorzaak van 
dyspneu. Om kortademigheid te kunnen beoordelen in SSc, kunnen mondocclusiedrukken 
gemeten worden als een index van de respiratoire drive, wat in hoofdstuk 5 wordt beschreven. 
Daarnaast kunnen deze drukken gemeten worden tijdens het inademen van CO2 en 
gerelateerd worden aan longfunctietesten. De normale waarden van mondocclusiedrukken 
(V’E/P0.1>8 l/min/cm H2O) zijn onafhankelijk van leeftijd en geslacht. Verder heeft de 
techniek een hoge reproduceerbaarheid binnen elk proefpersoon. In SSc­patiënten bleek 
een abnormale V’E/P0.1 een betere correlatie met de ernst van de dyspnoe te hebben 
dan traditionele longfunctieparameters. Verder bleek dat in deze patiënten de ΔP0.1/
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ΔPetCO2, als een index van de centrale chemoreceptorrespons op hypercapnie, significant 
hoger (abnormaler) te zijn dan bij SSc­patiënten met normale mondocclusiedrukken. 
Aangezien abnormale mondocclusiedrukken (V’E/P0.1<8 l/min/cm H2O) een sterke relatie 
hebben met een toegenomen pulmonale impedantie, kan deze test gemakkelijk gebruikt 
worden als een eerste diagnostische test voor de analyse van dyspnoe in de polikliniek. In 
hoofdstuk 6 wordt de perifere chemoreflex onderzocht in relatie tot patiënt­gerapporteerde 
inspanningsintolerantie. De perifere chemoreflex speelt een belangrijke rol in de controle 
van de ademhaling in rust en tijdens inspanning. Activering van deze chemoreceptor leidt 
gedurende de inspanning tot een respiratoire compensatie voor metabole acidose. Deze 
respons wordt gereflecteerd door een sterke toename van de ventilatoire equivalent voor 
CO2 aan het einde van de isocapnische bufferfase en een dalende eind­expiratoire pCO2. 
Naast een inspanningstest, kan de perifere chemoreflex gemeten worden door het verschil 
tussen de euoxische en hyperoxische ventilatoire respons op hypercapnie (eVHR­hVHR). 
Aangezien de ziekte SSc vooral een microvasculaire stoornis is, kunnen SSc­gerelateerde 
inflammatoire en fibrotische reacties in de halsslagader (glomus caroticum, carotid body) een 
verminderde perifere chemoreflex veroorzaken. In ons onderzoek trad bij alle SSc­patiënten 
een respiratoire compensatie voor de ontstane metabole acidose op. Echter, de eVHR­hVHR 
verschilde significant tussen de lcSSc­ en dcSSc­patiënten, wat een veranderde ademregulatie 
bij deze patiënten suggereert. Deze bevindingen kunnen de behandelend arts helpen om 
beter de gerapporteerde inspanningsintolerantie en dyspnoe bij inspanning te begrijpen. 
In hoofdstuk 7 wordt de relatie tussen longstructuur en longfunctie bestudeerd door middel 
van longdensitometrie en longfunctietesten. Data van een hoge resolutie CT­scan van de 
thorax (HRCT), een middel om kwantitatief de structuur van de hele long te analyseren, 
kunnen worden gekwantificeerd door middel van densitometrie. Daarom kan de kwantita­
tieve CT­densitometrie een gevoeliger instrument zijn om longweefsel te beoordelen dan 
het geoefende oog van de radioloog. Voor SSc hebben we de optimale score percentiele 
dichtheid in SSc geëvalueerd door kwantitatieve CT­densitometrie en vergeleken met 
longfunctietesten. Longvolume en de ne percentiele dichtheid (tussen 1 en 99%) van de gehele 
longen werden berekend uit CT­histogrammen. De n­percentiel dichtheid wordt gedefinieerd 
als de drempelwaarde van dichtheden, uitgedrukt in Hounsfield eenheden. Regressieanalyse 
voor de relatie tussen de DLCO als % van voorspeld en de n­percentiele dichtheid bleek 
optimaal op 85% (Perc85). Er was een significante correlatie tussen de Perc85 en de DLCO 
als % van voorspeld en de FVC als % van voorspeld. We concludeerden dat de optimale 
longdensitometrieparameter de 85e percentiel is (Perc85) en een longstructuurfunctierelatie 




in SSc aantoont. Deze resultaten bieden de mogelijkheid voor toekomstige studies om te 
bepalen of structurele veranderingen voorafgaan aan veranderingen in de longfunctie.
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